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Type 1 diabetes (T1D) is an autoimmune disease characterized by destruction of beta cells in the 
pancreas resulting in insulin deficiency, which leads to hyperglycemia and organ damage. T1D 
patients experience an increased risk of morbidity and mortality due to long-term complications, 
specifically retinopathy, nephropathy, and neuropathy. Studies demonstrating familial 
aggregation support the claim that a genetic contribution may influence the development of 
complications. This dissertation aims to identify genes/chromosomal regions that predispose 
T1D patients to, or protect them from, the expression of the chronic microvascular 
complications: retinopathy, neuropathy and nephropathy. 
In my first chapter, I introduce the history of type 1 diabetes and microvascular complications 
and their importance as a public health concern. Data show that the prevalence for T1D is 
increasing, and thus it is likely that the prevalence for the associated complications will also 
increase. Further, a large proportion of T1D patients develop at least one microvascular 
complication within 15 years of T1D diagnosis. By identifying risk alleles for the microvascular 
complications of T1D, the findings of this study could allow physicians to determine which 
patients are at greater/lesser risk for developing complications, help to develop interventions to 
delay or protect against the development of complications and thus reduce medical expenditure 
and suffering due to diabetes.  
In the second chapter, I provide the background for, and review the literature on, the genetics of 
T1D and microvascular complications. The genetic risk factors for T1D are well-established, but 
there is conflicting research on the question of whether T1D-predisposing HLA alleles may also 
be in part responsible for the occurrence of microvascular complications seen in T1D patients. 
We also investigate whether T1D HLA risk alleles are associated with all forms of microvascular 
complications or whether there are HLA alleles specifically associated with a given 
complication.  In the work described, I address these questions by examining the relationship of 
HLA alleles to the risk for any complication and to the risk for some specific complication.  
In the third chapter, I perform case-control analysis and evaluate known type 1 diabetes HLA 
susceptibility alleles and their association with microvascular complications. I used data from the 
Human Biological Data Interchange (HBDI), which includes 425 Caucasian families (2,506 
family members) with cases diagnosed with type 1 diabetes. Using a case-control study design 
nested on the cohort of the HBDI type 1 diabetes patients and their families, probands with at 
least one microvascular complication were considered cases, and the probands with T1D without 
microvascular complications (T1D only) were considered controls. Our findings suggest that the 
HLA class II DRB1*03:01 allele is a protective factor for complications, specifically for 
retinopathy, as is the DQA1*05:01-DQB1*02:01 haplotype. The DRB1*04:01 allele showed no 
evidence of association, except when the carriers of the protective DRB1*03:01 were removed 
from the analysis. Findings also showed a strong positive association between the HLA class I 
allele B*39:06 and complications. 
 In the fourth chapter, using the same sample of HBDI type 1 diabetes families that I used in 
Chapter 3, I perform linkage analysis and test markers along chromosome 6 for co-segregation 
with microvascular complications.  Using SNP data that were genotyped by the Center for 
Inherited Disease Research (CIDR), I performed linkage analysis examining 1) the phenotype of 
T1D itself, 2) the presence of any microvascular complication, 3) retinopathy alone, 4) 
nephropathy alone, and 5) neuropathy alone. Initially, we confirmed the linkage of the HLA 
locus to T1D. In subsequent analyses, using all complications as well as retinopathy alone as the 
phenotypes, we identified two linkage peaks; a linkage peak located at the HLA locus and 
another novel locus was telomeric to HLA. We did not find evidence for linkage for nephropathy 
alone or neuropathy alone.  
Findings from this dissertation show that both HLA and non-HLA regions are involved in the 
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Retinopathy, nephropathy, and neuropathy are chronic microvascular complications of type 1 
diabetes (T1D) and are responsible for much of the morbidity and mortality in T1D patients. 
Familial aggregation studies suggest that genetic susceptibility is a major risk factor for T1D. 
Familial aggregation studies, linkage studies and association studies all also support the claim 
that a genetic contribution may influence the development of microvascular complications as 
well (1-6). Although genetic association studies of microvascular complications have been 
conducted to identify specific alleles implicated in the development of complications, few 
studies have used linkage analysis to examine the genetics and inheritance of microvascular 
complications among T1D patients. 
In this chapter, I provide background and review the literature on the genetics of T1D and 
microvascular complications. The overall aim of this work is to identify genes that predispose 
T1D patients to, or protect them from, the development of microvascular complications.  One 
aim is to identify specific HLA DR/DQ alleles that influence the development to microvascular 
complications among T1D patients. There is conflicting research on the question of whether 
T1D-predisposing HLA alleles may be in part responsible for the differential occurrence of 
microvascular complications among T1D patients. Another aim is to identify genetic loci/genes 




1.2 Type 1 Diabetes - A brief history  
Diabetes has been described as far back as the first century. An ancient Greek physician, 
Aretaeus the Cappadocian, described people as emaciated with an “unquenchable thirst and 
trapped in an endless cycle of ‘excessive drinking’ and ‘making water’” (7). By the 19th century, 
as mortality rates due to infectious disease began to decline because of improvements in public 
health, diseases such as cancer, cardiovascular disease and diabetes began to receive more 
attention. In 1889, Mering and Minkowsi at the University of Strasbourg showed that diabetes 
was related to the malfunctioning of the pancreas, but they could not explain why some 
individuals did or did not develop the disease. Beginning in the early 20th century, physicians 
attempted to control the disease through dietary management, especially by calorie restriction, 
often to the point of starvation. 
In 1921-22, Frederick Banting and Charles Best discovered insulin. They gave pancreatic extract 
to a boy dying of type 1 diabetes. The boy’s extremely high blood sugar declined close to normal 
levels and in a matter of 24 hours, his life was saved. The discovery of insulin spread like 
wildfire across the world and changed a diagnosis of diabetes from being a virtual death sentence 
to what was considered a new lease on life. 
However, a decade after insulin’s discovery, mortality rates had not declined. Diabetes was 
ranked as the ninth leading cause of death in the US during the 1930s. In 1938, a Lancet editorial 
questioned, “Is diabetes a public health problem?” Physicians in both Europe and the US agreed 
that diabetes should no longer be considered just an individual disease, but had become a disease 
afflicting a population as well (7). While many diabetics found insulin to be a miracle, they also 




amputation. Many down-played the excitement, claiming that insulin was not a cure, but rather a 
tool to manage the disease. 
Since the description of diabetes two thousand years ago, generations of scientists have 
contributed volumes of research to understanding the etiology and pathogenesis of diabetes and 
its complications. Now that we have entered the 21st century, perhaps the next great step of 
discovery lies in studying diabetes-related complications on a genetic level. 
 
1.3 Microvascular complications as a Significant Public Health Concern 
Preventing the development of complications is one of the main goals of diabetes research. 
Retinopathy, nephropathy, and neuropathy are the chronic microvascular complications 
associated with T1D and are responsible for much of the T1D-associated morbidity and mortality. 
The pathophysiologic mechanisms for the development of microvascular complications involve 
hyperglycemia and oxidative stress, which result in tissue and organ damage in patients. The 
most frequent of the microvascular complications, retinopathy, is a leading cause of blindness 
and occurs in 50-90% of T1D patients (8). Diabetic nephropathy (DN) occurs in about 40% of 
T1D patients and leads to end-stage renal failure; DN is the leading cause of mortality among 
T1D patients (3). Diabetic neuropathy affects on average 30-50% of T1D patients (8). 
Neuropathy causes nervous system damage and presents with diverse clinical manifestations; 
lower leg amputation is among the most devastating medical interventions associated with 
neuropathy. 
While this dissertation focuses on T1D, research on complications may be relevant to all 
individuals with diabetes, regardless of its etiology. Type 2 diabetes is increasing alarmingly in 




the increasing prevalence of obesity. Diabetes and diabetic complications take an even heavier 
toll on the economically disadvantaged with limited health care. A better understanding of the 
genetic risk factors associated with the risk of developing complications is essential to aid in the 
identification of those most vulnerable to the complications of diabetes. 
1.3.1 Financial burden due to diabetes and microvascular complications 
The risk of death among diabetics (type 1 and type 2) is almost twice that for non-diabetics of the 
same age (http://diabetes.niddk.nih.gov/DM/PUBS/statistics/). Medical costs due to diabetes, 
disability and work loss result in enormous expenditure. The findings of our study can lead to 
genetic tests that would allow physicians to determine which patients are at greater/lesser risk for 










































CHAPTER 2:  







2.1 Type 1 Diabetes  
2.1.1 Epidemiology of Type 1 Diabetes 
Epidemiologic studies have demonstrated geographic differences in the incidence of T1D. Rates 
are generally highest in European Caucasian populations. Finland and Sardinia experience the 
highest incidence, >40/100,000/year and 37.8/100,000/year, respectively. Rates in the Baltic 
countries are lower than Scandinavian countries. Middle Eastern and as well as North African 
countries experience intermediate rates. T1D incidence is very low in Asia and in some Latin 
American countries. The lowest incidence rates have been reported in Venezuela and China, 
0.1/100,000/year and 0.1-4.5/100,000/year, respectively (1). These data demonstrate a 400-fold 
geographic variation in T1D incidence across populations worldwide. This variation is one of the 
largest observed for any noncommunicable disease. (2). One explanation for this dramatic 
variation may be related to the population frequency distribution of susceptibility alleles for T1D, 
particularly in the HLA genes. In section 1.3.6 (Genetic risk factors for T1D), I will discuss this 





(3) Figure 1. Geographical distribution of type 1 diabetes 
In the US, T1D incidence is considered high (although rates are lower than rates in Scandinavian 
countries) (4).  The incidence of T1D in the US was 18.3/100,000/year among children less than 
10 years of age and 19.7/100,000/year among individuals 10-19 years of age during 2002-2003 
(http://diabetes.niddk.nih.gov/dm/pubs/statistics/). There is also considerable ethnic variation in 
T1D incidence in the US. The estimated incidence for African-Americans is approximately 
3.3/100,000/year, while for Caucasians, it is approximately 20.6/100,000/year. In San Diego, CA, 
age-adjusted incidence rates for whites were 13.8/100,000/year, while the incidence rates for 
African-Americans, Asians, and Hispanics were 3.3/100,000/year, 6.4/100,000/year and 
4.1/100,000/year, respectively (2). 
Data on T1D incidence by gender appears inconclusive. According to Laporte and colleagues 
(1995), there is a slight male excess of T1D among Caucasians in the US. Between 1965-1989 in 
Allegheny County, PA, the incidence rates for males and females were 18.5/100,000/year and 
17.6/100,000/year, respectively. Among non-Caucasians, there was a slight female excess of 
T1D; male and female incidence rates were 8.6/100,000/year and 11.9/100,000/year, respectively. 
However, these gender differences have not been reported in other areas. Jefferson County, AL 
showed a female excess of T1D among both Caucasians and African-Americans (2). Kitagawa 
and colleagues showed a slight excess of females developing T1D in Japan, while in the US, 
Norway and Israel, there were no significant differences (5). Kitagawa and colleagues also 
compared the age of onset of T1D between males and females. They found that T1D occurs 
about a year earlier in females compared with males among US and Japanese children, but this 
difference was not seen among Israeli male and female children. These authors also claim that 




children less than 10 years of age compared with Caucasian Americans and Israelis. While 
gender data on T1D appears unresolved, differences seen between Asian, African-American, and 
Caucasian populations likely to relate to the frequency and distribution of high-risk susceptibility 
genes that vary between ethnic groups. Differences in genetic risk factors across populations will 
be discussed in greater detail below. 
2.1.2 Pathogenesis of Type 1 Diabetes 
T1D is a complex, autoimmune disease in which dendritic cells, macrophages and CD4+ and 
CD8+ T lymphocytes infiltrate the pancreas and destroy the insulin-producing β cells in the islets 
of Langerhans (6). This destruction results in loss of β cell function and insulin deficiency. The β 
cells sense the amount of glucose in the blood and release insulin to drive glucose into the cells 
and produce energy to carry out cellular functions. When β cell function is destroyed, patients 
lose the ability to maintain blood glucose concentrations in a physiologic range and this increases 
the risk for the development of diabetes-associated microvascular complications (eg. retinopathy, 
nephropathy, neuropathy).  
T1D has been shown to aggregate in families but does not follow a Mendelian pattern of 
inheritance. Rather, it is considered familial and with a complex genetic component. Disease 
initiation and progression are determined by multiple genetic and environmental factors. The 
development of T1D is believed to begin with a genetic susceptibility, which progresses to 
autoimmunity and ultimately to a total loss of insulin secretion. In genetically susceptible people, 
the initiating factor(s) promoting β cell destruction are unknown. Some theories include exposure 
to environmental toxins, early childhood viral exposure (eg. congenital rubella), or food allergies 





2.1.3 Clinical diagnosis of Type 1 Diabetes 
Early diagnosis and treatment of T1D is crucial so that the development of complications can be 
controlled. Classification and diagnostic criteria for diabetes have gone through several iterations 
over the previous decades. In 1979 and 1980, the National Diabetes Data Group (NDDG) in the 
US and the WHO Expert Committee classified diabetes into insulin-dependent diabetes (IDDM), 
non-insulin-dependent diabetes (NIDDM) and other types (7). In 1997, the American Diabetes 
Association (ADA) and the 1990 WHO report proposed a new classification based on etiology 
(7,8). Since IDDM and NIDDM patients are classified on the basis of treatment rather than 
etiology, these terms were eliminated and were replaced by ‘type 1’ and ‘type 2’ diabetes. Type 
1 includes cases characterized by an autoimmune process; it does not include cases with non-
autoimmune causes. Type 1 diabetes cases are detected by the presence of autoimmune 
antibodies, whereas type 2 is defined as a resistance to insulin action (7).  
The presence of autoantibodies is the first sign of beta cell autoimmunity. Four autoantibodies 
have been shown to predict T1D: classical islet cell antibodies (ICA), insulin autoantibodies 
(IAA), auto-antibodies to the 65 kD isoform of glutamic acid decarboxylase (GADA) and protein 
tyrosine phosphatase-related IA-2 molecule (IA-2A). Among children, diabetic symptoms 
(discussed in section 1.3.4) and the presence of autoantibodies are associated with an increased 
risk of developing overt T1D. While a positive test for a single autoantibody represents 
nonprogressive beta cell autoimmunity, detection of ≥2 autoantibodies indicates a progressive 
disease process and detection of 3-4 autoantibodies is associated with a 60-100% risk of 





Table 1. Diagnostic criteria for Type 1 Diabetes  
1. Symptoms of diabetes plus “casual” plasma glucose concentration ≥200 mg/dl. 
“Casual” is defined as any time of day without regard to time since last meal. The 
classic symptoms of diabetes include polyuria, polydipsia, and unexplained weight 
loss. 
2. Fasting plasma glucose (FPG) ≥126 mg/dl (7.0 mmol/l). Fasting is defined as no 
caloric intake for at least 8 h. 
3. 2-h postload glucose (PG) ≥200 mg/dl during an oral glucose tolerance test 
(OGTT). Epidemiologic studies use diabetes diagnosis based on FPG ≥126 mg/dl in 
the interest of standardization, when OGTT cannot be performed in the field 
(8) 
When a diabetes diagnosis is made, the detection of islet autoantibodies indicates that the 
diabetes is of an autoimmune origin. Islet autoantibody positivity is required to establish a T1D 
diagnosis (10). 
 
2.1.4 Symptoms of Type 1 Diabetes 
The pathology of T1D results in high levels of blood glucose (11). Some patients with mild 
metabolic abnormality may be asymptomatic. Other patients with hyperglycemia exhibit 
symptoms such as excessive thirst (polydipsia), frequent urination (polyuria) and unexplained 
weight loss and in severe cases, ketoacidosis may occur which can lead to unconsciousness and 




infants and in children younger than 5 years of age. In other patients, the process of beta cell 
destruction can continue for years before overt disease occurs (9). Long term complications 
include retinopathy (which can lead to blindness), nephropathy (which can lead to renal failure), 
and neuropathy (with risk of foot ulcers and amputation) (8). 
 
2.1.5 Risk factors for Type 1 Diabetes 
Prenatal and early life risk factors have been associated with the development of T1D. Many 
studies, including systematic reviews and meta-analyses, have been conducted to explore these 
factors, but the findings have been conflicting.  
One meta-analysis found that increasing maternal age increased the risk for T1D. The authors 
demonstrated that for each 5-year increase in maternal age, the odds of the child developing T1D 
increased 5% (OR=1.05) (12). In these cohort and case-control studies, response rates were 
lower among younger mothers, which could partially explain significant findings for advanced 
maternal age. Other studies have not found an association between maternal age and risk of T1D 
in the child. However, confounders such as socioeconomic status and maternal smoking status 
were not measured and adjusted for (13). Another meta-analysis identified higher birth weight as 
a small but significant risk factor for the development of T1D. The odds ratio for babies with 
birth weight between 3.5-4 kg and over 4 kg were 1.06 and 1.10, respectively, compared with 
babies weighing 3-3.5 kg (14). Other studies have failed to detect such an association (15,16). 
Not being breast-fed and exposure to cow’s milk early in life have been implicated as risk factors 
(17); however, a meta-analysis suggests that the weak association between infant diet and T1D 
may be due to bias (18). Maternal recall of infant diet is one of the largest sources of bias in T1D 




pediatrician’s recommendations compared with mothers of children without diabetes. This could 
result in an overestimate of the prevalence of certain risk factors. There is also accumulating, 
though not fully substantiated, evidence examining the role of viral infection in the development 
of T1D (19,20). Studies examining the association between viral infection and T1D suffer from 
study invalidity due to problems with study design such as small sample size or inappropriate 
control groups. As a result, the majority of studies do not provide convincing evidence for or 
against this relationship. 
 
2.1.6 Genetic risk factors for Type 1 Diabetes 
Particular HLA-DR and -DQ alleles/genotypes confer high risk for disease across ethnic groups. 
Linkage studies have demonstrated that the HLA region on chromosome 6p21 is the major 
known genetic determinant of T1D.  In Caucasian populations, HLA accounts for up to 50% of 
the genetic risk of T1D (21,22). The HLA region has shown linkage to T1D, with LOD scores 
exceeding 100 (23,24). Both the DRB1*03:01 and DRB1*04:01 alleles at the HLA-DR locus are 
strongly associated with T1D; over 90% of cases have at least 1 of those alleles compared with 
approximately 40% of controls (25). These findings have been repeatedly cited in the T1D 
literature (26-30). The DQ locus has an equally strong association with T1D (31). About 50% of 
children with T1D diagnosed before the age of 5 express the highest risk haplotype, 
DRB1*03:01 /04:01, DQA1*03:01-DQB1*03:02, and DRB1*03:01 /04:01, DQA1*05:01-
DQB1*02:01. The DR6 allele is the most protective HLA allele; approximately 20% of 
Americans and Europeans and fewer than 1% of T1D patients carry this allele (32).  
Studies have identified non-HLA T1D risk loci, which contribute smaller effects to susceptibility 




selection of autoreactive T cells, which mediate insulin tolerance. The region surrounding the 
insulin gene (INS) on chromosome 11p15 has been linked to T1D for over two decades 
(23,33,34). The main association was found around the INS-VNTR with a relative risk of 
approximately 3 (35). Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is expressed on CD4+ and 
CD8+ T cells and is critical for regulating self-tolerance and prevention of autoimmunity (36). 
CTLA-4 has been linked to T1D (23) and a specific allelic polymorphism has been consistently 
transmitted from heterozygous parents to affected offspring by TDT in multiple ethnic groups 
(37). A meta-analysis demonstrated a moderate effect of CTLA-4 on T1D, with a summary odds 
ratio of approximately 1.40 (38). A single base pair polymorphism in the coding region of 
protein tyrosine phosphatase non-receptor type 22 (PTPN22) has been shown to be associated 
with increased risk for T1D (39). It encodes the lymphoid-specific phosphatase (Lyp) and 
belongs to a family of proteins that are immune response regulators involved in downregulating 
T-cell activation. Several polymorphisms in the vitamin D receptor (VDR) have been associated 
with the risk for developing T1D, although there have been conflicting results (40,41). Smyth 
and colleagues conducted a GWAS and identified a T1D locus in the IFIH1 gene on 
chromosome 2q24.3, which is involved in the innate immunity against viral RNA (42).  
 
2.1.7 Geographic distribution of HLA and Genetic Susceptibility to Type 1 Diabetes 
The worldwide variation of T1D incidence is dramatic (43,44). As noted above, there is a 400-
fold worldwide variation in T1D incidence. Scandinavian countries have the highest incidence 
(approximately 40/100,000/year); Asian countries have the lowest (reported as low as 
0.1/100,000/year). This geographical variation reflects differences in the distribution of major 




susceptibility due to ethnicity or genetic background. One question is do the same HLA 
alleles/haplotypes show the same predisposing effects across populations? 
As noted above, linkage and association data have established the HLA region as the major 
susceptibility locus for T1D (21,45,46) with the HLA class II DRB1, DQA1 and DQB1 loci 
identified as the major HLA contributors to T1D expression (21,47,48). Subsequently, a 
hierarchy of predisposing, neutral and protective DR and DQ alleles and haplotypes that varied 
by ethnicity came to light. These differences reflected allelic heterogeneity within the HLA 
region (25,49,50).  
 With the dramatic variation of both T1D risk and allele/haplotype frequency across ethnic 
groups, many studies have investigated whether HLA alleles/haplotypes show the same 
predisposing effects across different ethnic populations (51,52).  
Determining the contribution of individual alleles at the HLA -DR and -DQ loci to T1D 
susceptibility can be unclear because of the strong linkage disequilibrium (LD) between 
alleles/loci. The strong LD between alleles at the HLA locus means it has proven difficult to 
determine which allele on a disease-associated haplotype is responsible for a genetic 
predisposition. One approach is to examine haplotypes in different ethnic groups with different 
allele frequencies and LD patterns. The following studies examined haplotypes in an attempt to 
identify predisposing genetic factors for T1D within the HLA region. 
Asian populations have lower disease prevalence and lower frequencies of the high-risk T1D 
haplotypes that are common in Caucasian populations. Nonetheless, even in Asian populations, 
the DR and DQ loci have the highest association with T1D (53). 
Thomson and colleagues examined whether the high-risk T1D DR-DQ haplotypes demonstrate 




analysis to examine the DRB1-DQB1 haplotype frequencies and T1D across African, Middle 
Eastern, Caucasian, Latin American, and East Asian populations. The authors found that the 
highly predisposing DRB1*03:01/DRB1*04:01 heterozygous genotype seen in Caucasians was 
was associated with increased risk in their overall meta-analysis as well as in the individual 
populations. They also demonstrated that DR3 (DRB1*03:01-DQB1*02:01) was a T1D 
predisposing haplotype worldwide, while the DR9 (DRB1*09:01-DQB1*03:03) haplotype is 
neutral worldwide. This meta-analysis concluded that the DR3 haplotype is rare in Asian 
populations compared with Caucasian populations, but that, when present, it maintains its 
predispositional effects. The DR9 haplotype, however, is more common in Asian populations 
compared with Caucasian populations, and, unlike its T1D-related neutrality in much of the 
world, is predisposing in Asian populations.  
Kawabata and colleagues examined the effect of –DR and –DQ haplotypes among Japanese and 
Korean populations (54). In a case-control study, the authors identified DR4 (DRB1*04:05-
DQB1*04:01) and DR9 (DRB1*09:01-DQB1*03:03) as high-risk susceptibility haplotypes in 
these Asian populations. In both populations, they found that the DR9 haplotype does not confer 
susceptibility to T1D in a heterozygous state, but rather a homozygous state is necessary to 
confer susceptibility to T1D. The converse was true for DR4. The association with T1D was 
stronger in a heterozygous state than in a homozygous state for DR4. The authors explained this 
differential effect of DR4 and DR9 on T1D susceptibility by postulating that if the DR4-encoded 
molecules have a higher binding affinity to a diabetogenic peptide compared with other 
haplotypes, they may induce autoimmunity even in a heterozygous state, in the presence of other 
class II molecules. In contrast, if DR9-encoded molecules have lower binding affinity to peptides, 




Ikegami and colleagues (55) examined the contribution of the HLA locus to T1D risk in a 
Japanese population. These authors presented similar findings to the report of Kawabata and 
colleagues. They showed a difference in the prevalence of disease-associated haplotypes between 
Japanese and Caucasian populations. They demonstrated that, although the DR3 (DRB1*03:01-
DQB1*02:01) and the DR4 (DRB1*04:01-DQB1*03:02) haplotypes are positively associated 
with T1D in Caucasian populations, in the Japanese, it is the DR4 (DRB1*04:05-DQB1*03:03) 
and DR9 (DRB1*09:01-DQB1*03:03) haplotypes that confer the strongest susceptibility. In the 
Japanese, DR9 in a heterozygous state (DR9/X, X≠9) has a neutral effect.  
In Caucasian populations, DQB1*03:02 is a strong susceptibility allele, but it is not associated 
with disease in Japanese. Kawabata et al. showed that the DQB1*03:02 allele is a susceptibility 
allele in Japanese populations, when in combination with susceptibility DRB1 alleles (e.g., 
DRB1*04:05, DRB1*04:07). The lack of association of this allele with T1D in Japanese 
populations is explained by its presence in combination with protective DRB1*04 alleles (e.g., 
DRB1*04:03, DRB1*04:06). In Asian populations, it is common for the protective DR4 
haplotype to co-occur with susceptible DQ haplotypes, while neutral/protective DQ haplotypes 
co-occur with the susceptible DR4 haplotypes. This counterbalancing of susceptible and 
protective/neutral haplotypes might be an important contributor to the low incidence of T1D in 
Asian populations (51). 
Park and colleagues (2001) compared susceptibility and transmission patterns of –DR and –DQ 
haplotypes among Korean and Caucasian T1D patients. These authors showed that DR3 and 
DR9 haplotypes had increased prevalence in Korean T1D subjects compared with controls. 
While haplotype frequencies are quite different in Korean and Caucasian populations, when 




that the susceptibility effects of the DRB1-DQB1 haplotypes are consistent in Korean and 
Caucasian populations (51). 
Population frequencies of DR/DQ alleles and haplotypes vary between ethnic groups, as do the 
associations between DR/DQ alleles and T1D risk. It is the presence/absence of haplotypes in 
populations that may explain why different haplotypes are associated with disease among 
different ethnic groups. As noted, the disease-associated DR3 and DR4 haplotypes in Caucasians 
are rare in Asian populations and therefore cannot contribute to the majority of T1D 
susceptibility (but when present, they would be expected to be associated). However, the Asian-
specific DR4 (DRB1*04:05-DQB1*04:01) and DR9 haplotypes common in Asian populations 
are almost absent in Caucasian populations, and do not contribute to T1D susceptibility in 
Caucasian populations.  
In a transracial study, Park and colleagues (51) identified that DR and DQ haplotypes transmitted 
from nondiabetic parents to diabetic offspring were similar for Korean and Caucasian families. 
These authors make the claim that while the frequency and association of DR/DQ 
alleles/haplotypes and T1D may differ across ethnic groups, the effect of an individual 
allele/haplotype on T1D susceptibility is consistent across populations.  
These studies, which have investigated HLA frequency distribution and susceptibility among 
different ethnic groups, have identified some possible explanations for the differences in 
worldwide T1D incidence rates. Aside from factors that may be responsible for producing real 
differences in the worldwide incidence of T1D, there may be some methodologic factors that 
influence the measurement of these differences. We cannot ignore such factors that may 
contribute to these differences such as, small sample sizes, the difficulty of finding multiplex 




non-HLA genes, as well as unknown environmental factors that likely vary between 
geographical regions.  
 
2.2 Microvascular complications 
2.2.1 Origin and clinical diagnoses of microvascular complications 
A. Retinopathy 
Retinopathy, the most frequent of microvascular complications, is a leading cause of blindness 
and occurs in 50-90% of T1D patients (56). The majority of individuals with T1D develop some 
degree of retinal damage. A smaller proportion of individuals develop severe retinopathy. Retinal 
microvascular signs in diabetic patients include microaneurysms, lipid deposits, intraretinal 
microvascular abnormalities, haemorrages. Vision loss results from macular edema and 
neovascularization of the retina includes haemorrhage and retinal detachment.  Retinal arteriolar 
dilation increases retinal capillary pressure, which leads to capillary wall dilatation 
(microaneurysms), leakage and rupture (haemorrhages) (57). Chronic exposure to hyperglycemia 
is thought to lead to microvascular changes and retinal damage (56). 
 
B. Nephropathy 
Clinically, diabetic nephropathy (DN) is characterized by persistent proteinuria, decreased 
glomerular filtration, and increased blood pressure. The pathophysiology involves renal 
extracellular matrix accumulation and thickening of the glomerular basement membrane. Kidney 
complications begin with microalbuminuria (small amounts of albumin leaking into the urine) 
and progresses to overt, persistent proteinuria. Both are predictors of renal failure for T1D 




Approximately 30-40% of T1D patients are at risk to develop DN (59,60). End-stage renal 
failure develops in approximately 20% of T1D patients (61). The literature points to familial 
clustering of DN, suggesting a genetic effect in the development of kidney complications (62).  
 
C. Neuropathy  
Diabetic neuropathies are heterogeneous in symptoms, neurologic involvement, and underlying 
mechanisms (63).  Different parts of the nervous system can be affected and may present with 
diverse clinical manifestations. On average, diabetic neuropathy affects 30-50% of type 1 
diabetes patients. The most common are chronic sensorimotor distal symmetric polyneuropathy 
(DPN) and diabetic autonomic neuropathies (DAN). DPN frequently involves burning pain, 
electrical sensations, deep aching pain, as well as decreased sensation (loss of vibration, 
temperature, or pain perception). Symptoms are most commonly experienced in the feet and 
lower limbs. DAN is a disorder of the autonomic nervous system. It can involve cardiovascular, 
gastrointestinal, and urogenital systems (63,64). 
 
2.2.2 Factors implicated in the development of microvascular complications 
A. Risk factors for microvascular complications 
i. HbA1c as a risk factor for microvascular complications 
The relationship between hyperglycemia and complications has been well-established in T1D 
and T2D, where uncontrolled plasma-glucose concentrations can lead to serious sequelae. The 
Diabetes Control and Complications Trial (DCCT) and the UK Prospective Diabetes Study 
(UKPDS) demonstrated a relationship between the rise of blood glucose levels and the increased 




demonstrated that when people with type 1 or type 2 diabetics reduce blood glucose 
concentrations close to normal glycemic ranges, measured as glycosylated hemoglobin A1c 
(HbA1c), the incidence of diabetes-associated complications was also significantly reduced. 
Since publication of the DCCT study, HbA1c has become the gold standard for evaluation for 
diabetes treatment. The American Diabetes Association (ADA) recommends measuring HbA1c 
twice per year for those whose HbA1c level is lower than 7% and more frequently for those 
whose levels are higher (http://www.diabetes.org/living-with-diabetes/treatment-and-care/blood-
glucose-control/a1c/). Glycosylated hemoglobin is a pairing of hemoglobin with glucose inside 
the red blood cell. The HbA1c test measures the percentage of glycosylated hemoglobin 
(HbA1c) in the blood and provides an overview of the average blood glucose over the past 2-3 
months. In a nondiabetic person, about 5% of all hemoglobin is glycosylated. In the case of 
diabetes, increased concentrations of glucose enter the blood stream, more hemoglobin is 
glycosylated, and the resulting HbA1c levels are higher. High HbA1c level is a well-established 
risk factor in the development of long-term diabetic complications.  
While HbA1c measures glycemic control for the previous 2 to 3 months, it does not provide 
information regarding glycemic variability in a given day.  In the DCCT study, conventionally 
treated patients were more likely to be exposed to glycemic instability since they had fewer 
insulin injections per day compared to the intensively treated patients. Authors of the DCCT 
study suggested that complications may be dependent on the degree of glycemic variability. 
Kilpatrick (2009) claimed that HbA1c and duration of diabetes explained only 11% of the 
variation in the risk of retinopathy in the DCCT study, suggesting that factors independent of 
HbA1c must explain 89% of the variation (67). Other studies have shown that normalizing 




Overall, why some patients with poor metabolic control do not develop complications, while 
other patients with good metabolic control develop complications, remains unresolved and a 
source of scientific debate that requires further inquiry (69,70). Zhang and colleagues attempted 
to delve deeper into this issue. These authors concluded that retinopathy develops in 
approximately 10% of patients with good metabolic control and over 40% of patients with poor 
metabolic control and they isolated baseline glycemic exposure as a predictor (“baseline” defined 
as a patient’s glycemic exposure at the start of the study). High baseline glycemic values increase 
the risk of developing complications despite good metabolic control. 
The reduction of blood glucose levels may be causally related to the reduced risk of 
complications. However some patients with poor glycemic control do not develop complications, 
and some with good glycemic control do develop complications (62,69,71). Hence HbA1c may 
not adequately explain risk of complications (72). Studies suggest that HbA1c may be under 
genetic control and may influence the development of diabetes-related complications (73,74). In 
a twin study, Sneider and colleagues (2001) found that MZ twins concordant and discordant for 
T1D showed significant correlations of HbA1c (75). Paterson and colleagues (2010) identified a 
major locus for HbA1c levels in type 1 diabetics by GWAS, indicating that HbA1c may be under 
genetic control (76).  
HbA1c values are not available in my dissertation dataset. While it would be beneficial to 
include these values, it appears from the literature that HbA1c may not be a necessary predictor 
of complications. Consequently, the absence of this variable is not an impediment to detecting a 






ii. Other risk factors for microvascular complications 
In addition to HbA1c, other risk factors have been implicated in the development of 
microvascular complications.  
Risk factors for retinopathy include duration of diabetes, hyperglycemia, increased blood 
pressure, ethnic origin, dyslipidaemia, puberty, pregnancy, duration of diabetes, diet and 
smoking (77,78).  
The risk factors for nephropathy include hyperglycemia, hypertension, duration of diabetes, 
protein overload and smoking (79). 
Risk factors for neuropathy include level of hyperglycemia and duration of diabetes. Other risk 
factors are unknown (79). 
Ethnicity appears to be an independent predictor for microvascular complications, after 
controlling for metabolic control and other retinopathy risk factors, such as age, sex, diabetes 
duration and blood pressure. The prevalence and severity of retinopathy is higher in African 
Americans, Hispanic and south Asians than in Caucasians (56,80). Prevalence of end-stage renal 
failure appears to be higher among blacks and Latinos compared with whites. Possible 
explanations for these differences may include certain behavioral characteristics, for example, 
disparities in diabetes knowledge and treatment adherence, access to care, physician perceptions 
or racial discrimination. Alternatively, unmeasured environmental factors or differences in 
genetic susceptibility may contribute to prevalence differences among ethnic groups (81).  
While ethnicity, age of onset of diabetes, duration of diabetes, blood pressure and lipid control 
are some of the known risk factors for the development of complications in general (66,82,83), 
studies have also suggested that genetic predisposition is a risk factor for the development of 




B. Genetic risk factors 
i. Familiality of microvascular complications 
Hyperglycemia and diabetes duration are important risk factors in the development of 
microvascular complications. However even after years of poor glycemic control, some patients 
remain free of complications; and conversely, patients with good glycemic control may still 
develop complications (62,69). Many investigators have hypothesized that genetic susceptibility 
is a contributing risk factor that leads to the development of microvascular complications. 
Results from family studies of both T1D and T2D support this claim. Studies have demonstrated 
familial clustering of DN (84,86).  In T1D families, diabetic siblings of patients with diabetic 
nephropathy are significantly more likely to develop this disease compared with diabetic siblings 
of probands without diabetic nephropathy (86). A South Indian sib pair analysis demonstrated 
strong familial clustering of diabetic kidney disease among type 2 diabetics. In a twin study, 
Leslie and colleagues (1982) demonstrated concordance of retinopathy in 35 of 37 identical type 
2 diabetic twins and in 21 of 31 identical type 1 diabetic twins (87). Since this study does not 
include dizygotic twins, it is difficult to interpret these findings as simply genetic, since 
monzygotic twins share the same environment as well.  
 
C. Evidence for microvascular complications with specific genes. 
In this review, the vast majority of early studies used cases and controls to examine the 
frequency difference of class I/II HLA alleles among retinopathy or nephropathy cases with T1D 
compared with controls (T1D only). The vast majority of later studies used the candidate gene 
approach, while only a few used genome-wide association or linkage analysis. While the 




and selecting their study populations were valid. The control subjects used in these studies were 
free of complications for at least 15-20 years after the onset of T1D, though in one study, 
controls were free of complications for at least 10 years. Sampling controls in this manner 
ensures that those selected are truly unaffected and one can be reasonably sure that control 
patients are unlikely to ever develop complications. The study populations were ethnically 
homogeneous in the vast majority of these studies, for example, Caucasian Finnish type 1 
diabetics, or Caucasian Danish type 1 diabetics, or in some cases, just Caucasian type 1 diabetics 
were sampled. Using homogeneous study populations increase the likelihood of sampling 
individuals from homogeneous genetic backgrounds and thus minimize the chances of 
introducing population stratification, which can lead to increased false positives and false 
negatives.  
i. Retinopathy (Table 2) 
Several early studies and some later studies have reported associations with HLA DR alleles, 
particularly the role of HLA DRB1*04:01 and the development of retinopathy (88-91); however 
other studies have failed to confirm these associations (92-97). Dornan et al (1982) reported that 
the presence of retinopathy was significantly associated with DRB1*04:01 (OR=3.7) (88). 
Malone et al. (1984) confirmed the association with DRB1*04:01, but only if it was in 
combination with the DRB1*03:01 allele. Authors reported that these alleles in combination 
occurred more frequently among patients with proliferative retinopathy compared with those free 
of retinopathy (89). Cruickshanks et al (1992) demonstrated that the DRB1*04:01 allele was a 
significant risk factor for retinopathy, but only among individuals who were negative for 




Other investigations, however, have not reported associations between DR alleles, specifically 
DRB1*04:01 and retinopathy (94-99).  
Aldose reductase (ALR2) is the gene that encodes the first, and rate-limiting enzyme in the 
polyol pathway of glucose metabolism. Studies have suggested that polymorphisms in and 
around this gene are associated with diabetic retinopathy. Demaine and colleagues (2000) found 
an association of the Z-2 allele in the aldose reductase gene with diabetic retinopathy (OR=2.33) 
(100,101). In two separate case-control studies using French Caucasian individuals, Taverna and 
colleagues demonstrated significant associations between vitamin D receptor (VDR) SNPs and 
severe retinopathy (102,103). Al-Kateb and colleagues (2007) found associations of eight 
VEGFA SNPs with severe retinopathy in a prospective cohort survival analysis over 15 years 
using 1,369 Caucasian individuals with T1D (104). According to Rudofsky and colleagues 
(2008), heterozygous or homozygous carriers of the M55V polymorphism in the SUMO4 gene 
show a reduced risk of diabetic retinopathy (OR=0.37, p-value=0.004) (105). In a case-control 
study using 124 Caucasian individuals with T1D, Hovnik and colleagues (2009) found a 
significant association between MnSOD Val/Val genotype and T1D patients with retinopathy 
(106). Grassi and colleagues (2011) conducted a genome-wide meta-analysis and identified a 
signal (rs227455) associated with severe diabetic retinopathy in the intergenic region between 
two unnamed genes, LOC728275 and LOC728316 (107). Charles and colleagues (2011) 
identified a SNP (rs2236624) in the adenosine A2A receptor that was associated with a decreased 
risk of developing proliferative diabetic retinopathy (108). Adenosine is a physiologic mediator 






ii. Nephropathy (Table 3) 
While some reports have indicated that DRB1*04:01 is a risk allele for retinopathy, other studies 
have indicated contrary findings for the relationship between DRB1*04:01 and the development 
of nephropathy. An early study (1986) reported that the DRB1*04:01 allele was protective for 
nephropathy in a Danish population (91). In a more recent study using subjects of European 
ancestry (GoKinD study), researchers examined the relationship between carriers of HLA 
DRB1*04:01 and the development of nephropathy. The authors reported that proband carriers of 
DRB1*04:01 were 50% less likely to have nephropathy compared with probands who do not 
carry any DRB1*04:01 alleles (90). However in two separate studies using Caucasian European 
subjects, authors failed to report any association between DRB1*04:01 and nephropathy (92,93). 
These investigators claim that HLA is unlikely to have a major influence in the susceptibility to 
nephropathy in Caucasian European cohorts. Two linkage scans for type 1 diabetics were 
performed in Caucasian populations (120, 121). Both studies reported evidence for linkage of 
diabetic nephropathy on chromosome 3q.  
In a study using 275 British Caucasian individuals, Heesom and colleagues showed a decrease in 
the frequency of the Z+2 allele and an increase in the Z-2 allele in the aldose reductase gene 
among patients with nephropathy (109). Vionnet and colleagues (2006) found an increased risk 
for nephropathy with a polymorphism in the adiponectin gene by both association and TDT 
analyses. (110). Al-Kateb and colleagues (2007) found an association between a SNP in the 3’ 
region of the superoxide dismutase 1 (SOD1) gene and severe nephropathy (111). Osterholm and 
colleagues (2006) conducted a genome wide linkage scan for type 1 diabetic nephropathy using 
460 families using 83 discordant sib-pairs from Finland (112). They reported suggestive linkage 




association with a SNP rs1866813 at the 3q22 locus (113). Möllsten and colleagues performed a 
case-control study using 755 T1D patients from Denmark. In this study, being a carrier of the V 
allele at the V16A polymorphism in the SOD2 gene is significantly associated with increased 
risk of diabetic nephropathy (114).  In 2009, Pezzolesi and colleagues conducted a genome-wide 
association scan and identified two associations for SNPs near the FRMD3 and CARS genes (61). 
In 2011, Kure and colleagues identified a nonsynonymous SNP located in exon 8 of the MMP-12 
gene that significantly reduced the risk of diabetic nephropathy (115).  
 
iii. Neuropathy (Table 4) 
The development of diabetic neuropathy may also involve genetic susceptibility. Vague and 
colleagues (1997) conducted a candidate gene case-control study examining the association of 
Na/K ATPase gene with neuropathy in 81 Caucausian individuals with T1D. They found a 
significant association between a SNP in the ATP1 A1 gene (a Na/K ATPase gene) and 
peripheral neuropathy (116). Decreased Na/K ATPase activity in the nervous tissue has been 
implicated in the development of neuropathy. In a candidate gene case-control study using 
Caucasian individuals, Donaghue and colleagues (2005) and Heesom and colleagues (1998) 
demonstrated that the aldose reductase Z-2 allele confers risk for the development of neuropathy 
(117,118). Oxidative stress results in high levels of reactive oxygen species (ROS), which in 
excess, causes damage to tissues, such as oxidation of lipids, proteins, depletion of antioxidants, 
enzyme inactivation, DNA breakage (119). PARP-1 is a nuclear enzyme that is activated in 
response to DNA damage. Nikitin and colleagues (2008) performed a candidate gene case-




polymorphisms in the coding region of PARP-1 which are strongly associated with diabetic 
polyneuropathy in Russian T1D patients (120).  
With the exception of the aldose reductase gene, which has been implicated in all three 
microvascular complications, these genetic association studies have implicated genes unique to 
each complication. 
 
 2.3 Does the risk for one complication increase the risk for a second complication? 
There is little published research investigating whether all three microvascular complications 
involve similar etiological pathways, and whether the development of one complication 
predisposes toward the risk of developing a second complication. A review by Girach and 
colleagues (2006) identifies interrelationships among all three diabetic microvascular 
complications, where the presence of one complication increases the risk for developing a second 
complication (121). El-Asrar and colleagues (2002) found that T1D with retinopathy were 
almost 14 times, and T2D patients retinopathy almost 4 times as likely and to have nephropathy 
than those T1D and T2D patients without retinopathy (122). Monti and colleagues demonstrated 
that a complication in a sibling increased the risk for a complication in the proband (OR=9.9) 
(83). The EURODIAB Complications study reported a positive association between the degree 
of retinopathy and level of albuminuria. Schmechel & Heinrich (1993) demonstrated that 
individuals with retinopathy exhibited proteinuria more often than individuals without 
retinopathy and that the prevalence of proteinuira increased relative to the increasing severity of 
retinopathy (123). Parving and colleagues (1988) showed that the prevalence of neuropathy and 
retinopathy was higher in patients with microalbuminuria compared with normoalbuminuria 




but are not very well understood. If there are similarities in the pathogenesis of each of the 




2.4 Summary and Conclusion 
In summary, type 1 diabetes is an autoimmune disease characterized by destruction of beta cells 
in the pancreas resulting in insulin deficiency, which leads to hyperglycemia and organ damage. 
T1D patients experience an increased risk of morbidity and mortality due to long-term 
complications, specifically retinopathy, nephropathy, and neuropathy. While glycemic control is 
a risk factor for the development of complications, even normalizing HbA1c does not eliminate 
the risk of developing complications. Studies demonstrating familial aggregation support the 
claim that a genetic contribution may influence the development of complications. Further, 
associations among complications have been noted, where the presence of one complication may 
increase the risk for developing a second complication.  
To date very little is known about the inheritance of microvascular complications. There have 
been a number of association studies implicating specific alleles for microvascular complications. 
The vast majority of these studies used the candidate gene approach. Few previous studies have 
used linkage analysis to identify genetic loci for diabetic complications. They have not examined 
all three microvascular complications as one phenotype, which considers the possibility of a 
common genetic susceptibility. In this dissertation, I use statistical methods to identify genetic 
risk factors predisposing T1D individuals to, or protecting from, the development of 
microvascular complications (Chapter 3). I use linkage analysis to identify genetic susceptibility 
loci to microvascular complications (Chapter 4). Linkage will identify large chromosomal 
regions that may contain susceptibility loci with large genetic effects. Finally, I summarize the 
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Table 2. Studies investigating predisposing (or protective) genes/loci with retinopathy 




Risk allele / 
SNP 





Dornan et al 
Diabetes 1982 
HLA DRB1*04:01 3.7 127 Caucasian 
T1D patients 
Case-control 




P < 0.001 74 T1D patients Case-control 




NS 99 T1D patients Case-control 








Stewart et al 
Diabetologia 1993 
HLA DR alleles NS 102 T1D 
patients 
Case-control 
Falck et al 
J Diab Comp 1997 
HLA Class I and II 
alleles 
















Mimura et al 
Am J Ophthal 
2003 
HLA Class I and II 
alleles 




Demaine et al 
Invest Ophthal & 
Vis Science 2000 
Aldose 
Reductase 






Taverna et al.  









Al-Kateb et al 
Diabetes 2007 


















SUMO4 M55V OR=0.37 (0.004) 223 T1D 
patients 
Case-control 



























Grassi et al. Hum 




Rs227455 p-value=1.6x10-7 2,829 T1D 
patients 
Case-control 

















Table 3. Studies investigating predisposing (or protective) genes/loci with nephropathy 
Author / 
Journal / Year 
Gene/ 
region 
Risk allele / 
SNP 
Effect size / p-value Study 
population 
Study design 





P<0.02 317 T1D 
Danish patients 
Case-control 
Ronningen et al 
Diabetes Res 
1993 
HLA  Class II 
alleles 
NS 114 T1D 
patients 
Case-control 
Chowdhury et al 
Diabetologia 
1999 
HLA Class I and II 
alleles 




Cordovado et al 
Diabetes 2008 
HLA DRB1*04:01 P<0.0001 829 European 
T1D patients 
Case-control 
Moczulski et al 
Diabetes 1998 
3q AT1 P=7.7 x 10-5 66 Caucasian 
sib-pairs  
Linkage 
Osterholm et al 
Kidney Intl 2006 


















Vionnet et al 
Diabetes 2006 












He et al AJHG 
2009 





Mollsten et al 
Diabetologia 
2009 
SOD2 V16A / 
rs4880 
OR=1.5 (0.036) 441 Danish 
T1D patients 
Case-control 












Kure et al  
Mol Genet 
Metab. 2011 
MMP-12  Asn357Ser/ 
rs652438 










Table 4. Studies investigating predisposing (or protective) genes/loci with neuropathy 
Author / 
Journal / Year 
Gene/ 
region 
Risk allele / 
SNP 
Effect size / p-value Study 
population 
Study design 
Vague et al 
Diabetologia 
1997 
ATP1 A1 Bgl II 
polymorphism 
Chisq=35.6 (0.0001) 81 Caucasian 
T1D patients 
Case-control 





Z-2 OR=3.02  




Nikitin et al 


























Although HLA alleles are associated with type 1 diabetes, association with microvascular 
complications remains controversial. We tested HLA association with complications in multiplex 
type 1 diabetes families. 
 
Probands from 425 type 1 diabetes families from the Human Biological Data Interchange 
(HBDI) collection were analyzed. The frequencies of specific HLA alleles in patients with 
complications were compared with the frequencies in complications-free patients.  The 
complications we examined were: retinopathy, neuropathy, and nephropathy. We used logistic 
regression models with covariates to estimate odds ratios.  
 
We found that the DRB1*03:01 allele is a protective factor for complications (OR=0.58; p = 
0.03), as is the DQA1*05:01-DQB1*02:01 haplotype (OR= 0.59; p = 0.031). The DRB1*04:01 
allele showed no evidence of association (OR=1.13; p = 0.624), although DRB1*04:01 showed 
suggestive evidence when the carriers of the protective DRB1*03:01 were removed from the 
analysis. The class II DQA1*03:01-DQB1*03:02 haplotype was not associated with 
complications but the class I alleles B*39:06 (OR=3.27; P = 0.008) and B*44:02 (OR=3.19; P = 
0.027) showed strong positive association with complications.  
 
Our results show that in type 1 diabetes patients, specific HLA alleles may be involved in 





3.2 Introduction  
Type 1 diabetes represents a major health problem, and data show that its prevalence is rising [1]. 
By year 2030, over 3 million people are predicted to have type 1 diabetes in the US alone [2], 
(American Diabetes Association). As more people develop type 1 diabetes, the prevalence of the 
associated complications also increases. The major pathologies related to type 1 diabetes are the 
chronic microvascular complications: retinopathy, nephropathy, and neuropathy. These 
complications are responsible for much of the morbidity and mortality in patients, leading to 
blindness, end stage renal disease, neuropathy and consequent amputation in many patients. 
Previous work has shown that while the type 1 diabetes-associated complications may be the 
result from persistent high blood sugar, they are also familial, suggesting the existence of a 
genetic contribution to these phenotypes [3-6]. However, the findings from studies of the 
genetics of microvascular complications are inconclusive and controversial (see Discussion) [7-
22]. 
 
Type 1 diabetes is a complex, autoimmune disease in which dendritic cells, macrophages, CD4+ 
and CD8+ T lymphocytes infiltrate the pancreas and destroy the insulin-producing β cells in the 
islets of Langerhans [23]. The Human Leukocyte Antigen (HLA) region on chromosome 6p21 is 
the major susceptibility locus for type 1 diabetes. The class II loci, HLA–DRB1, -DQA1 and -
DQB1, have the strongest effects on type 1 diabetes risk. Specifically, the haplotypes with the 
highest risk for type 1 diabetes among Europeans are DRB1*03:01-DQA1*05:01-DQB1*02:01 / 
DRB1*04:01-DQA1*03:01-DQB1*03:02 [24,25]. The class I HLA genes have also been 
implicated in type 1 diabetes risk, but these alleles have smaller effects on type 1 diabetes than 




[27],  their role in the development of microvascular complications is less clearly understood. 
Some studies have reported significant associations of retinopathy or nephropathy with HLA 
class I or II alleles [7,8,14-22], while other studies have failed to report such associations [9-13].  
 
In this study, we examined the association of HLA alleles with type 1 diabetes-related 
complications in a large Caucasian cohort. We report newly observed associations of 
complications with specifically chosen HLA alleles. These hypothesis-driven statistical 
associations may shed light on genetic influences that affect susceptibility to complications. 
 
3.3 Materials and methods  
 
3.3.1 Family identification and data collection  
Families were ascertained through the presence of at least one family member with type 1 
diabetes (the “proband”); most families were multiplex for type 1 diabetes, i.e., there were at 
least two affected offspring per family. HBDI designated probands were used as the proband 
cases and controls. Families were invited to be part of the Human Biological Data Interchange 
(HBDI) data collection through a series of advertisements sent to the entire mailing list of the 
Juvenile Diabetes Foundation International (JDFI) during the period 1988–1990 [28]. All 
member families were asked to complete a standardized confidential questionnaire sent by mail 
and the responses were added to the HBDI database. The questionnaire was administered to the 
proband (or parents, if the proband was a child) and also to additional family informants. 
Inquiries included demographic, medical, genealogical, and familial information about 





3.3.2 HBDI data 
Our dataset included 425 families with cases diagnosed with type 1 diabetes before age 30. There 
were 2506 family members included from the HBDI database as of the end of 2004. Families 
were selected for inclusion in the HBDI sample based on the presence of at least one type 1 
diabetes patient per family. Multiplex ( > 1 case per family) families were preferentially sought. 
In this sample, all participants were diagnosed with type 1 diabetes. All patients in this study 
sample are Caucasian. A total of 49% of all subjects were female. We emphasize that, for this 
study, only 1 individual (the proband) per family was used in the analyses. 
 
3.3.3 Assessment and definition of diabetes and diabetic complications 
We included only patients with type 1 diabetes diagnosed before 30 years of age who required 
insulin treatment. The accuracy of the self-reported information with respect to presence/absence 
of complications (e.g. presence of retinopathy, yes or no) was evaluated by: 
1) Including extra questions about related conditions in the questionnaire. The presence of 
macular edema or complete or partial blindness were considered indicators of retinopathy; the 
presence of end- stage renal failure, kidney failure, or repeated high urinary albumin levels were 
considered indicators of nephropathy. In cases of inconsistencies (e.g. presence of macular 
edema but not retinopathy), further investigations were carried out through phone interviews, 
around the time of data collection. 
2) Data available from follow-up were used to confirm or update the presence/absence and 




Starting in 2004, follow-up questionnaires have been periodically sent to a subset of families to 
obtain updated information about development of complications, new cases of diabetes, and 
related medical history data, with 1000-2000 families targeted each year (for further description, 
please see (3)). 
3) Collecting medical records. For the subset of patients [n=179] with medical records available, 
the presence of type 1 diabetes and complications was verified according to American Diabetes 
Association guidelines [29-32]. 
4) Information indicating absence of a complication in a subject was considered reliable only if 
the subject was without that complication for at least 15 years after type 1 diabetes onset. 
 
3.3.4 Type 1 diabetes subjects and complications  
 Of the 425 probands in the sample, 128 had at least one complication, and 297 were free of 
complications. The majority of cases that had any complication had retinopathy (93.0%), fewer 
cases had nephropathy or neuropathy (Table 1). 
 
3.3.5 Study design 
We used a case-control study design nested on the cohort of the HBDI type 1 diabetes patients 
and, for some analyses, their affected siblings. The probands with at least one microvascular 
complication were considered cases, and the probands without microvascular complications were 
considered controls. Every proband, whether case or control, has type 1 diabetes. 
To identify genetic risk factors for microvascular complications, the presence of an allelic risk 
predictor was considered the exposure. The outcome variable was defined as the presence of any 




neuropathy as separate outcomes. However, results for nephropathy and neuropathy are not 
reported due to small sample sizes. We included sex, age at type 1 diabetes diagnosis, and 
duration of type 1 diabetes as covariates to control for environmental factors that may influence 
the development of microvascular complications.  
 
3.3.6 HLA genotyping 
Genotyping of the HBDI cohort was performed by sequence-specific oligonucleotide probe 
(SSOP) technology and has been described previously [33-36]. Briefly, relevant polymorphic 
exons for each locus (exon 2 for class II alleles and exons 2 and 3 for class I alleles) were 
amplified by polymerase chain reaction with biotinylated primers, denatured, and hybridized to 
an array of unlabeled oligonucleotide probes (corresponding to known polymorphic sequence 
motifs) on a backed nylon membrane. Hybridization was visualized with a colorimetric detection 
system, and probe binding patterns were interpreted using Sequence COmpliation and 
REarrangement software (SCORE™) [37]. The HBDI collection was included as one of the 
extant cohorts in Type 1 Diabetes Genetics Consortium (T1DGC), and the HBDI samples were 
re-genotyped at higher resolution, with updated SSOP reagents, to ensure uniformity of 
resolution in the HLA genotyping data in the T1DGC [24,26,38,39].  
   
3.3.7 Statistical analysis 
We performed logistic regression among type 1 diabetes probands to determine associations with 
microvascular complications. We calculated odds ratios (ORs) and 95% confidence intervals 
(CIs), adjusting for sex, age of type 1 diabetes diagnosis (using 5-year intervals) and duration of 




yrs, 29-38 yrs, >38 yrs (approximately equal numbers of individuals in each category).  As with 
an earlier study [3], we included sex as a covariate in the logistic regression. Age at type 1 
diabetes diagnosis and duration were also included as covariates since these factors may be 
influential for the onset and development of complications. HLA alleles were included in the 
regression models as independent predictors for microvascular complications. Each HLA allele 
or (in the case of DQ-encoding loci) haplotype encoding the heterodimeric protein (e.g., 
DRB1*03:01, DRB1*04:01, DQA1*05:01-DQB1*02:01, DQA1*03:01-DQB1*03:02, B*39:06, 
B*44:02) was analyzed in separate regression models.  A two tailed test was used and a p < 0.05 
was considered statistically significant. All of the analyses were performed using the statistical 
package Stata 10.1 (Stata Corp., College Station, TX, 2003). 
 
3.3.8 Multiple Testing 
Correction for multiple tests was not required in our primary analysis of four HLA factors (2 
DRB1 alleles and 2 DQA1-DQB1 haplotypes): DRB1*03:01 and DRB1*04:01 alleles and the 
DQA1*03:01-DQB1*03:02 and DQA1*05:01-DQB1*02:01 haplotypes. These four hypotheses 
were chosen a priori on the basis of prior knowledge that these four HLA factors are strongly 
associated with type 1 diabetes.  
 
In an exploratory analysis of the HLA class I loci, multiple alleles were tested with the aim of 
generating hypotheses that could be tested in a larger follow-up study. These tests were based 
upon either the high prevalence of a particular allele in the population or prior association of type 




population (>30%) or because of prior knowledge: A*01:01, A*02:01, B*08:01, B*39:06, 
B*44:02, C*07:01. 
 
3.4 Results  
3.4.1 Patient characteristics  
The clinical and familial characteristics of our study population are summarized in Table 1. The 
distribution of each microvascular complication among probands is summarized in Table 2. We 
performed the χ2 test for gender and Student’s t-test for duration of type 1 diabetes. For the 425 
type 1 diabetes probands in the study, the mean durations of type 1 diabetes in complications 
cases (n=128) and controls (n=297) were 39.4 +/- 8.90 years and 31.2+/- 9.71 years, respectively. 
The difference in the mean duration of diabetes between cases and controls was statistically 
significant (p<0.0001). However, according to Student’s t-test, age of type 1 diabetes diagnosis 
did not show a statistically significant difference, nor did gender, according to the χ2 test.   
 
3.4.2 MHC Class II genes analyses  
The distribution of HLA DRB1*03:01, DRB1*04:01, DQA1*05:01-DQB1*02:01, and 
DQA1*03:01-DQB1*03:02 alleles/haplotypes among the probands is shown in Table 2. Among 
the 425 probands, 19% of probands did not express either DRB1*03:01 or DRB1*04:01 alleles 
and 14% had neither the DQA1*05:01-DQB1*02:01 nor DQA1*03:01-DQB1*03:02 haplotype 
(data not shown). Sixty-two percent of probands had at least one DRB1*03:01 allele, and 49% of 
probands had at least one DRB1*04:01 allele. Sixty-five percent were positive for at least one 





Table 3 provides unadjusted and adjusted ORs for the presence of one or more microvascular 
complications (e.g., retinopathy, nephropathy, neuropathy) using specific HLA alleles as 
predictor variables. Table 4 shows the unadjusted and adjusted ORs for retinopathy alone.  The 
adjusted estimates are controlled for sex, age at type 1 diabetes diagnosis, and duration of type 1 
diabetes.  Using a multivariable logistic regression model, adjusting for covariates, the presence 
of a DRB1*03:01 allele was protective both for one or more microvascular complications 
(OR=0.58, 95% CI 0.35-0.95) and for retinopathy alone (OR=0.58, 95% CI 0.35-0.96), which 
was the most frequent complication in the dataset.  In the multivariable logistic regression model 
for DRB1*04:01, no relationship between DRB1*04:01 and microvascular complications was 
found for either retinopathy alone  (OR=1.17, 95% CI 0.72-1.92) or for one or more 
microvascular complications (OR=1.13, 95% CI 0.70-1.81).  
 
Thus, unlike the results for DRB1*03:01, the presence of DRB1*04:01 shows little evidence of 
influence on the risk for complications. We observed a similar trend (i.e., DRB1*03:01 appears 
mildly protective, while DRB1*04:01 appears neutral) for nephropathy, but the OR did not reach 
statistical significance. Such a trend was not observed for neuropathy, but the sample size 
precluded detecting all but the strongest effects. 
 
We examined the association of DQ haplotypes with the risk for one or more microvascular 
complications and the risk for retinopathy alone (Tables 3 & 4). DQA1*05:01-DQB1*02:01 
(which is in linkage disequilibrium with DRB1*03:01) was significantly protective for the 
presence of one or more complications (OR=0.59, 95% CI 0.37-0.95) and for retinopathy (OR= 




also had a DRB1*03:01 allele (except for three individuals who were DRB1*03:01-positive and 
DQA1*05:01-DQB1*02:01-negative), the strong linkage disequilibrium between these two 
alleles means it is difficult to determine the origin of the protective effect.   There was no 
influence of DQA1*03:01-DQB1*03:02 on either retinopathy or one or more complications.  
 
3.4.3 MHC Class I genes analyses  
To better guide future studies involving the genetics of microvascular complications, we sought 
to identify specific HLA class 1 genes that might warrant further consideration. We chose six 
independent class I risk alleles based on prior knowledge related to T1D or because of the high 
prevalence of these alleles in our study population; only the HLA-B*39:06 allele demonstrated a 




After adjusting for covariates in multivariable logistic regression models, the HLA-B*39:06 
allele showed a notable increased risk for one or more complications (OR=3.27, 95% CI 1.36-
7.89), and for retinopathy alone (OR=3.34, 95% CI 1.34-8.30). We also observed elevated risks 
for nephropathy alone and neuropathy alone, but these were not statistically significantly (data 
not shown). The mean durations of those positive (n=32) and negative (n=380) for the B*39:06 
allele were 33.98 +/- 10.27 years and 30.86+/- 8.91 years, respectively. The difference in the 
mean durations was not statistically significant (P=0.097). When stratifying on duration, the 









Before adjusting for covariates, the HLA*B44:02 allele showed an increased risk for one or 
more complications (OR=2.02, 95% CI 1.12-3.66). After adjusting for covariates, this allele did 
not retain statistical significance for one or more complications. In multivariable logistic 
regression models, neuropathy was highly significantly associated with the presence of HLA-
B*44:02 (OR=3.19, 95% CI 1.14-8.95, number affected = 9 (25.7%), number unaffected = 29 
(9.8%), data not shown). The HLA-B*44:02 allele did not demonstrate a statistically significant 
effect for nephropathy alone. 
 
3.5 Discussion  
Our results suggest that, in type I diabetes, HLA- DRB1*03:01 or DQA1*05:01-DQB1*02:01 
(or an allele in linkage disequilibrium with these alleles) protects against the presence of 
complications. The evidence is strongest for protection specifically against retinopathy.  
 
3.5.1 MHC Class II genes and complications risk: Current study and past work  
 
In our covariate-adjusted models, both DRB1*03:01 and DQA1*05:01-DQB1*02:01 were 
significant protective factors for both for the presence of more than one microvascular 




in our data arises mostly from the retinopathy phenotype. Analyses of the DRB1*04:01 allele, on 
the other hand, suggest its presence influences the risk for complications. Cruickshanks et al. 
[22] reported an association of retinopathy with HLA- DRB1*04:01, among those negative for 
HLA-DRB1*03:01  (DRB1*04:01/X, X≠ DRB1*03:01), an observation similar to one seen in 
our analyses. Cruickshanks et al. found that type 1 diabetes patients with HLA- DRB1*04:01, 
who were negative for HLA- DRB1*03:01 were significantly more likely to have proliferative 
retinopathy (OR=5.43, 95% CI 1.04-28.30) than those negative for both alleles. However in a 
follow-up study, Wong et al. [13] investigated the effect of HLA- DRB1*03:01 and 
DRB1*04:01 on the development of diabetic retinopathy and they failed to observe a 
relationship between HLA- DRB1*03:01 or DRB1*04:01 and diabetic retinopathy. Dornan et al. 
[17] reported that DRB1*04:01 was a risk allele for retinopathy. The Cruickshanks et al. [22] 
study and our study also found DRB1*04:01 was a risk allele but only in subjects without 
DRB1*03:01.  Jensen et al. [16] examined the effect of DRB1*03:01-DQA1*05:01-
DQB1*02:01 and DRB1*04:01- DQA1*03:01-DQB1*03:02 haplotypes and the risk of 
retinopathy after 15 years of type 1 diabetes duration. Consistent with our findings, they 
observed that DRB1*03:01-DQA1*05:01-DQB1*02:01 is protective, but their findings were not 
statistically significant. They also reported, as we found here, that the DRB1*04:01- 
DQA1*03:01-DQB1*03:02 haplotype was neither a risk factor nor protective for developing 
retinopathy, although they did not examine the effect of the DRB1*04:01 allele without the 
presence of the DRB1*03:01 allele. Contrary to our findings and to those by Jensen et al., 
Agardh et al. [7] reported that the DRB1*03:01-DQA1*05:01-DQB1*02:01 haplotype was more 
frequent in patients with severe retinopathy. Concerning nephropathy, Svejgaard et al. [18] and 




we did not identify DRB1*04:01 as a protective allele for any of the complications, Svejgaard et 
al. and the GoKinD work do support the notion that HLA is involved in the development of 
microvascular complications. Other studies, however, failed to report any association of 
DRB1*03:01 or DRB1*04:01 with either retinopathy or nephropathy [9-15]. 
 
Thus, the earlier literature is somewhat contradictory, although most of the studies report an 
association of HLA class II alleles with some complications.  
 
Among some of the possible reasons for these contradictory results involve differences in 
ascertainment. Whether one examines “retinopathy” or “proliferative retinopathy”, the definition 
of which diabetes patients are cases and which are controls, as well as analysis techniques used, 
all play a role. For example, in our sample, it is may be that severe retinopathy was more likely 
to be noted in a self-report than mild retinopathy. The GoKinD study [8] and Rogus et al.’s [40] 
samples defined controls as not having nephropathy after at least 10 years diabetes duration.  Our 
controls had type 1 diabetes for at least 15 years and 90% had diabetes for more than 20 years. 
Heitala et al. [41] included patients with type I diabetes onset age greater than 35 years. Our 
sample is one of the few that used probands from families multiplex for type I diabetes. The 
absence of retinopathy among the controls in these genetically loaded families suggests genetic 
factors played a greater role in protection from complications because of the strong evidence that 
inherited factors influence risk for complications [3-6]. Thus, while there can be several 
explanations for the contradictory results in the literature, the number of studies finding 






3.5.2 Effect of DRB1*03:01 vs. DRB1*04:01 
Since DRB1*03:01 appears to have a protective effect on the risk of complications, we 
investigated the effect of DRB1*04:01 on its own, in the absence of DRB1*03:01  (i.e., 
excluding individuals who were heterozygous for DRB1*03:01 and DRB1*04:01). In an 
adjusted multivariable regression model, we observed a stronger positive association between 
DRB1*04:01 and the risk for retinopathy (closer to, but not reaching, statistical significance; 
OR=1.74, p-value=0.069; data not shown) compared with a model in which heterozygous 
DRB1*03:01/ DRB1*04:01 individuals were included. The failure to reach significance could be 
due to decreased sample size, because a quarter of the study population was heterozygous for the 
excluded DRB1*03:01/ DRB1*04:01 genotype. In a further examination, when stratifying on 
DQA1*03:01-DQB1*03:02, we observed that the DRB1*04:01 allele was associated with an 
even greater elevated risk of retinopathy. In the absence of DQA1*03:01-DQB1*03:02, 
DRB1*04:01 becomes a significant risk factor for the risk of retinopathy with borderline 
statistical significance (OR=2.67, 95% CI 0.94-7.60). In the presence of DQA1*03:01-
DQB1*03:02, the DRB1*04:01 allele does not influence risk of complications (data not shown). 
While the sample size is too small to confidently assert this putative risk effect of DRB1*04:01 
(17 DRB1*04:01 individuals in the absence of DQA1*03:01-DQB1*03:02), it is worthy of 
conducting further research to investigate whether an increased risk exists.  
 
3.5.3 MHC Class I genes  
After covariate adjustment, we found that the presence of the HLA-B*39:06 allele was 




complications. HLA-B*39:06 has also been reported to be associated with the risk for type 1 
diabetes risk, whether conditioned on the class II DR-DQ alleles or not [26,36,42]. However, no 
previous study has identified this allele as a risk factor for complications [14].  
 
Other studies have reported associations between different class I alleles and microvascular 
complications in the Japanese population [14,20,21]. In an earlier study, Nakanishi et al. reported 
an association between HLA-A24 and retinopathy [20], and in a more recent study, Nakanishi et 
al. reported that the HLA-A24 allele was associated with early beta cell loss and with early 
development of diabetic retinopathy [21]. Mimura et al. investigated the relationship between 
HLA and proliferative diabetic retinopathy (PDR) and reported a higher frequency of the HLA-
B62 and Cw4 alleles among type 1 diabetics with PDR compared with the non-PDR group [14]. 
These findings aside, the relationship between HLA class I alleles and complications has not 
been widely explored. Although among studies reporting associations, findings have been 
inconclusive [11,12,14,20,21]. 
 
3.5.4 Effect of age-of-onset of type I diabetes 
Onset of complications is influenced by type 1 diabetes duration, and previous research suggests 
that age at onset and progression to type 1 diabetes are directly linked to the MHC class II genes 
[43]. Early age of type 1 diabetes onset is commonly associated with the high risk haplotypes 
HLA DRB1*03:01-DQA1*05:01-DQB1*02:01 and DRB1*04:01-DQA1*03:01-DQB1*03:02, 
especially the very high risk heterozygous genotype comprised of these two haplotypes [44,45]. 
This association with early onset suggests a stronger genetic predisposition to disease than other 




20 years duration of type 1 diabetes [31,46]. Up to 40-50% of patients develop nephropathy or 
neuropathy within 15-20 years of the onset of type 1 diabetes [46]. Among probands in the 
current study, the average duration of type 1 diabetes was almost 34 years, the average age of 
diagnosis for type 1 diabetes was approximately 9 years of age. On average, the duration of type 
1 diabetes in our sample exceeds the peak risk of 15-20 years for both case and control probands 
and thus variation in duration is unlikely to influence these analyses. In our data, DRB1*03:01-
positive subjects do not have later onset of disease than DRB1*03:01-negative subjects, however 
we retained the duration variable in the adjusted models because cases had a significantly longer 
duration of disease than controls. 
 
3.6 Advantages and limitations  
Our study examined complications as the phenotype of interest because complications are 
ultimately responsible for much of the morbidity and mortality seen with type 1 diabetes. Other 
HLA studies that have examined complications suffer from small sample sizes. Our work has the 
benefit of using one of the larger type 1 diabetes multiplex family-based datasets in the world 
(meaning that genetic factors may be more prominent among the subjects used in our study), a 
dataset that also has information on all three microvascular complications. One limitation in our 
study is that we do not have HbA1c measurements or data on other environmental factors such as 
smoking status that may influence the development of complications, although smoking status is 
unlikely to be associated with any particular HLA allele or haplotype. Previous work has 
established that reducing blood glucose concentrations close to normal glycemic ranges also 
significantly reduces the incidence of diabetes-associated complications (although, in a recent 




indicate that HbA1c may not adequately explain the risk for complications. Some patients with 
poor glycemic control do not develop complications, and some with good glycemic control 
develop complications [4,49,50]. The literature indicates that HbA1c may not be a necessary 
predictor of complications and consequently it does not impede our ability to detect genetic risk 
factors for complications. Further, while our data include information on the presence/absence of 
complications, we lack information on the age of onset of complications. Information on age of 
onset would enable more accurate analyses. Survival analysis, for example, would be more 
powerful than a case-control design, however we are precluded from doing survival analysis 
because we have no data on the timing of complications’ onset. Nonetheless, our current data 
provide a solid indication that genes influence the expression of complications and suggest that 
HLA plays a role in risk. 
 
3.7 Conclusion 
In conclusion, these data indicate that, in addition to their strong association with disease 
susceptibility, HLA alleles and haplotypes are also associated with microvascular complications 
of type 1 diabetes.  The formal possibility exists that the classical HLA loci themselves are not 
involved, but that alleles at other loci in linkage disequilibrium with the diabetes risk alleles are 
responsible for our findings.  Lastly, further research needs to be conducted in separate study 
populations to validate these findings. Confirmation of these results could provide greater 
insights into the mechanisms leading to the development of microvascular complications. 
Ultimately, the findings of our study could lead to the ability to stratify risk of developing 
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Table 1. Characteristics of type 1 diabetes by numbers of total proband  














a’Case’ refers to a proband with type 1 diabetes and at least 1 microvascular complication.  
 ‘Control’ refers to a proband with type 1 diabetes only and no history of microvascular 
complications. 




Characteristic Cases Controls 
No. of subjects (in 425 families) 128 297 
Females (n, %) 60 (46.9) 132 (44.4) 
Age of type 1 diabetes diagnosis 
(yr±SD) 
8.7 ± 5.3  9.1 ± 7.1 
Duration of type 1 diabetes 
[yr±SD]b 
39.4 ± 8.9 31.2 ± 9.7 
Retinopathy (n, %) 119 (93.0) N/A 
Nephropathy (n, %) 46 (35.9) N/A 
Neuropathy (n, %) 35 (27.3) N/A 


























65 (54.6) Nephropathy 
alone 
5 (10.9) Neuropathy 4 (11.4) 
Retinopathy + 
Nephropathy 
23 (19.3) Retinopathy + 
Nephropathy 





13 (10.9) Nephropathy 
+ Neuropathy 





18 (15.1) All 3 
complications 











Table 3. Results of logistic regression models for one or more microvascular complications 














No. of DR-typed 
subjects 
400 120  280   
DRB1*03:01-negative 151 (37.7) 54 (45.0) 97 (34.6) Referent Referent 





0.58 (0.35, 0.95), 
0.030 









1.13 (0.70, 1.81), 
0.624 
No. of DQ-typed  
subjects 
425 128  297    
DQA1*03:01-
DQB1*03:02-negative 


























0.59 (0.37, 0.95) 
0.031 
No. of HLA-B-typed  
subjects 
425 128  297    






HLA-B*39:06-positve 32 (7.5) 13 (10.2) 19 (6.4) 1.65 (0.79, 
3.46) 
0.182 
3.27 (1.36, 7.89) 
0.008 






HLA-B*44:02-positve 52 (12.2) 23 (18.0) 29 (9.8) 2.02 (1.12, 
3.66) 
0.02 
1.85 (0.94, 3.62) 
0.074 


















No. of DR-typed subjects 400 
 
111 289   
DRB1*03:01-negative 151 (37.7) 50 (45.1) 101 (34.9) Referent Referent 
DRB1*03:01-positive  249 (62.3) 61 (54.9) 188 (65.1) 0.66 (0.42, 1.02), 
0.063 
0.58 (0.35, 0.96), 
0.031 
DRB1*04:01 -negative 205 (51.3) 52 (46.8) 153 (52.9) Referent Referent 
 
DRB1*04:01 -positive 195 (48.7) 59 (53.2) 136 (47.1) 1.28 (0.82, 1.98) 
0.275 
1.17 (0.72, 1.92), 
0.520 
No. of DQ-typed  
subjects 
425 119  306    
DQA1*03:01-
DQB1*03:02-negative 




275 (64.7) 76 (63.9) 199 (65.0) 0.95 (0.61, 1.48) 
0.821 








246 (57.9) 60 (50.4) 186 (60.8) 0.66 (0.43, 1.00), 
0.053 
0.58 (0.36, 0.95) 
0.029 
No. of HLA-B-typed  
subjects 
416 119  297    
HLA-B*39:06-negative 385 (92.5) 107 (89.9) 278 (93.6) Referent Referent 
 
HLA-B*39:06-positve 31 (7.5) 12 (10.1) 19 (6.4) 1.64 (0.77, 3.50) 
0.199 
3.34 (1.34, 8.30) 
0.01 
HLA-B*44:02-negative 366 (88.0) 98 (82.4) 268 (90.2) Referent Referent 
 
HLA-B*44:02-positve 50 (12.0) 21 (17.6) 29 (9.8) 1.98 (1.08, 3.64) 
0.027 
1.77 (0.89, 3.55) 
0.106 






Linkage Analysis: Genomic Regions Contributing to the Expression of  
Type 1 Diabetes Microvascular Complications 
 






We conducted linkage analysis aimed at identifying susceptibility loci for microvascular 
complications. We used 415 genotyped families with cases diagnosed with type 1 diabetes before 
age 30 from the Human Biological Data Interchange (HBDI). Our most significant results were 
found on chromosome 6, so we restricted our further analyses to SNPs on chromosome 6 using 
402 markers. We performed an analysis of linkage to the phenotypes of 1) the presence of any 
microvascular complication, 2) the presence of retinopathy alone, 3) the presence of nephropathy 
alone, 4) the presence of neuropathy alone. We also did an analysis with the phenotype of T1D. 
The contrast between the analysis with complications as the phenotype and the analysis with 
T1D as the phenotype ensures that the observed linkage peaks using complications as the 
phenotype are, in fact, related to the expression of complications, rather than to the expression of 
T1D. Initially, we confirmed the influence of the HLA locus on T1D expression. In subsequent 
analyses, using “any complication” as the phenotype, we identified two linkage peaks: a linkage 
peak located at the HLA locus and another, novel locus telomeric to HLA. These same two peaks 
also were evident when retinopathy alone was the phenotype. We did not find evidence for 
linkage for nephropathy alone or neuropathy alone. We then stratified on families whose 
probands were positive for DRB1*03:01 or DRB1*04:01. When we only used DRB1*03:01-
positive families in the analysis, the HLA peak was observed but there were also two novel loci, 
one telomeric and one centromeric to HLA. When we stratified on DRB1*04:01-positive 
families, again the HLA peak appeared, followed by two novel loci, both telomeric to HLA. The 
linkage peaks based on the DRB1*03:01-positive families were only suggestive of linkage 




three peaks based on DRB1*04:01-positive families either reached or exceeded the significant 
threshold for linkage (HLOD>3). Based on large differences in the LOD scores, we argue that 
the DRB1*03:01-positive and DRB1*04:01-positive groups are genetically distinct and have 
different genetic influences, a finding in accordance with the observation that DRB1*03:01 is 
protective for retinopathy. Our findings showed that both HLA and non-HLA loci are involved 
in the expression of complications, specifically for retinopathy alone. While the HLA region is a 
major contributor to the expression of T1D, there may be an interaction between specific HLA 






Retinopathy, nephropathy, and neuropathy are chronic microvascular complications and are 
responsible for much of the morbidity and mortality in type 1 diabetes (T1D). Data indicate that 
the prevalence of T1D is rising (1) and, thus, the prevalence of the complications associated with 
T1D will also increase. Identifying factors that influence the expression of complications is 
crucial to determining how to treat and possibly prevent them. 
 
Type 1 diabetes is a complex autoimmune disease in which dendritic cells, macrophages, CD4+ 
and CD8+ T lymphocytes infiltrate the pancreas and destroy the insulin-producing β cells in the 
islets of Langerhans (2,3). Previous work has shown that T1D-associated complications may 
result from persistent high blood sugar. In addition, evidence of the familiality of complications 
has also been clearly demonstrated, which suggests a possible genetic contribution to these 
phenotypes (4-7). Many genome-wide linkage analyses have focused on identifying 
susceptibility loci for T1D and studies have consistently found evidence that the Human 
Leukocyte Antigen (HLA) region on chromosome 6p21 is the major susceptibility locus for T1D. 
However, there have been few studies investigating genetic influences on the expression of 
complications.  
 
The class II loci, HLA–DRB1, -DQA1 and -DQB1, have the strongest effects on risk for T1D. 
The alleles with the highest risk for type 1 diabetes among Europeans are DRB1*03:01 and 
DRB1*04:01 (8).  Of the few linkage analyses focused on identifying susceptibility loci for 




effect of the HLA region on risk for T1D, to our knowledge there have been no linkage studies 
aimed at investigating the influence of the HLA locus on the expression of complications.  
 
In this study, we describe linkage analyses aimed at identifying susceptibility loci for 
microvascular complications among families of patients with T1D. We focus on chromosome 6 
to determine whether high-risk susceptibility alleles for T1D contribute to the expression of 
complications and, in addition, if there are novel loci that also contribute to the expression of 
complications. Further, we sought to determine if previously unknown loci are observed with 
specific microvascular complications (e.g. retinopathy alone) and whether these loci interact with 
alleles for TID at the HLA locus.  
 
4.3 METHODS 
4.3.1 Family recruitment and data collection  
Families were ascertained through the presence of at least one family member with type 1 
diabetes (the “proband”). Families were invited to be part of the Human Biological Data 
Interchange (HBDI) data collection through a series of advertisements sent to the entire mailing 
list of the Juvenile Diabetes Foundation International (JDFI) during the period 1988–1990 (13). 
All member families were asked to complete a standardized confidential questionnaire sent by 
mail and the data were added to the HBDI database. The questionnaire was administered to the 
proband (or parents if the proband was a child) and also to additional family informants. The 






4.3.2 HBDI data 
Our dataset included 427 families with cases diagnosed with type 1 diabetes before age 30. There 
were 2576 family members in the 427 families included in the HBDI database as of the end of 
2004. Families were selected for inclusion in the HBDI sample based on the presence of at least 
one type 1 diabetes patient per family, although multiplex families were preferentially sought. Of 
the 427 HBDI ascertained families, twelve families were excluded from the analysis due to 
missing genotype information; thus, there were a total of 415 families and a total of 2,544 
individuals. Forty-nine percent of all subjects were female. 
 
4.3.3 Assessment and definition of diabetes and diabetic complications 
For these analyses, we included only patients with type 1 diabetes diagnosed before 30 years of 
age who required insulin treatment. The accuracy of the self-reported information with respect to 
presence/absence of complications (e.g. presence of retinopathy, yes or no) was evaluated by: 
1) Including extra questions about related conditions related to these complications in the 
questionnaire. Reports of macular edema or complete or partial blindness were considered an 
indicator of retinopathy; reports of end- stage renal failure, kidney failure, or repeated high 
urinary albumin levels were considered an indicator of nephropathy. In cases of inconsistencies 
(e.g. report of macular edema but not retinopathy), further investigations were carried out 
through phone interviews. 
2) Data available from follow-up were used to confirm or update the presence/absence and 
progression of complications. 
3) Collecting medical records. For the subset of patients (n=179) with medical records available, 




Association guidelines (14-17). 
4) Information indicating absence of a complication in a subject was considered reliable only if 
the subject was without that complication for at least 15 years after type 1 diabetes onset. 
 
4.3.4 Type 1 diabetes subjects and complications  
 From the families sent for genotyping, 239 individuals had at least 1 microvascular 
complication: 219 individuals had retinopathy, 87 had nephropathy, and 76 had neuropathy.  
 
4.3.5 Genotyping 
A total of 5,966 SNP markers were genotyped, with an average of 0.58-cM spacing across the 
genome. Genotyping was performed by the Center for Inherited Disease Research (CIDR), a 
division of the National Human Genome Research Institute. Our genome-wide analysis did not 
yield significant results, so we restricted our analyses to SNPs on chromosome 6 using 402 
markers.  
 
4.3.6 Phenotype definitions 
Separate linkage analyses were performed using the following phenotype definitions: 1) the 
presence of any microvascular complication, 2) the presence of retinopathy, 3) the presence of 
nephropathy, 4) the presence of neuropathy.  
 
We defined “affected” as T1D patients with complications and T1D patients without 
complications as “unaffected” (T1D only). Individuals without T1D were excluded from these 




inheritance (18) . 
 
We also performed an analysis of linkage to the phenotype of T1D.  For the T1D analysis, we 
defined “affected” as individuals with T1D (without complications). The “unaffected” group was 
defined as individuals without T1D (clinically normal).  
 
4.3.7 Analysis Overview 
In the initial analysis, by excluding T1D patients with complications and their families, we 
sought to confirm genomic regions that were linked to T1D in this dataset. The purpose of 
analyzing T1D alone as a phenotype was to determine whether genomic regions that were 
identified when complications were the phenotype could also be seen with the T1D phenotype. 
Subsequently, we conducted a series of analyses to identify genomic regions that were linked to 
complications, regions that may be the same or different than the loci observed for the presence 
of T1D. This contrast ensures that the observed linkage peaks in which complications are used as 
the phenotype are, in fact, related to the expression of complications, rather than to the 
expression of T1D. 
 
Linkage analyses for complications were performed using all families with at least one 
“affected” family member and one “unaffected” family member, or families with at least two 
affected members (e.g., there had to be at least two siblings with T1D, at least one of whom had 






4.3.8 Linkage analysis 
Linkage analysis was performed using LOD (“logarithm of odds”) score analysis. Multipoint 
LOD scores and multi-point heterogeneity LOD scores (HLOD scores) were calculated using the 
Genehunter program (19). We assumed both dominant and recessive modes of inheritance (20). 
A dominant gene frequency of 0.006 and a recessive gene frequency of 0.1 were used. For all 
linkage analyses, we report linkage findings that were maximized over the mode of inheritance 
(20,21) and penetrance level. Subsequently, for all reported analyses, we assumed a dominant 
mode of inheritance, and 50% penetrance.  
 
4.3.9 Pedigree stratification for high-risk alleles using T1D with complications as the phenotype 
In previous work (Lipner et al, in press, Human Immunology), we demonstrated that the 
DRB1*03:01 allele provided a significant protective effect on the risk of complications, 
specifically on retinopathy alone. Therefore, we explored the influence of specific HLA alleles 
by performing a linkage analysis in subsets of families that were grouped according to the 
presence of either DRB1*03:01 or DRB1*04:01 in the proband. The four phenotypes we 
analyzed were: 1) the presence of any complication, 2) retinopathy alone, 3) nephropathy alone 
and 4) neuropathy alone. Families in which the proband carried a DRB1*03:01 or DRB1*04:01 
allele and had a microvascular complication were included in these analyses. Our aim was to 
identify genomic regions associated with complications among families that were identified by 
the proband’s –DR status. Figure 1 describes the numbers of families with complications and the 







4.4.1 Distribution of affected (T1D +complications) and unaffected (T1D only) individuals 
within families 
Among all families, 50 families (12%) had exactly 2 family members with T1D and no 
unaffected family members (T1D only families), 68 families (16%) had one affected and one 
unaffected family member (mixed families). 210 families (51%) had 2 siblings with TID only 
and no family members with microvascular complications. The remaining 87 families (21%) 
contained either a single individual with complications or more than 2 individuals with various 
combinations of complications/no complications s (Table 1). 
 
Of the 415 families and 2,544 total family members, 536 people were not genotyped, and of 
these 470 (88%) did not have T1D, leaving a total of 2,008 family members who were available 
for linkage analysis. In the sample population for linkage, family members were classified as 
those with or without T1D, and T1D with or without microvascular complications. Among 
individuals with genotyping information, 1140 (56.8%) were without T1D, 629 (31.3%) had 
T1D but no complications, and 239 (11.9%) had T1D and complications. All patients in this 
study sample are Caucasian.  Among those with at least one complication, the prevalence of 
retinopathy was 91.6%, the prevalence of nephropathy was 36.4%, and the prevalence of 
neuropathy was 31.8% (Table 2). 
 
4.4.2 Linkage analysis with type 1 diabetes as the phenotype 
To locate the linkage signal(s) for the phenotype of T1D, and to determine if that signal 




on chromosome 6 in which the affected phenotype was T1D alone. Only families in which T1D 
individuals did not have complications were classified as “affected” for this T1D phenotype 
analysis (n=629). Family members without T1D were classified as “unaffected” (n=1140). 
Family members with T1D and complications were classified as unknown (n=239). We observed 
a highly significant linkage signal (HLOD=28.5, LOD=28.0) in the HLA region (50.8-52.3 cM) 
(Figure 2), which was expected and replicates many previous studies (22-25).  
 
4.4.3 Linkage analysis with the ‘presence of any complication’ as the phenotype 
When we analyzed the data for linkage with the phenotype “presence of any complication” 
defined as affected, we found that, in addition to the single peak centered on the HLA region 
(presumably detecting linkage predominantly to T1D, although there is evidence that HLA 
influences the expression of complications also (see below)), there are indications of two 
separate genetic influences for complications, lying outside the HLA region (Table 3A, Figure 
3), one telomeric and one centromeric to the HLA region. The linkage signal(s) for 
complications is statistically significant at the genome-wide level (HLOD>3) for two of the three 
peaks (HLOD=3.27 for the peak at position 42.85 cM, telomeric to HLA, and HLOD=3.61 for 
the peak at HLA itself at position 52.37 cM). A third peak, centromeric to the HLA peak, was 
below the threshold for genome-wide linkage (HLOD=1.53 at position 61.01 cM). To confirm 
whether these linkage signals were due to loci related to complications and not arising from 
artifacts of strong linkage between HLA and T1D, we compared the pattern of linkage peaks 
found in the analyses of complications with the linkage pattern for T1D in families with no 
complications. When the phenotype was T1D only, we observed only the linkage peak centered 




observed in the presence of complications, not among those with the T1D alone phenotype.  
 
4.4.4 Linkage analysis with retinopathy as the phenotype 
When “retinopathy” was the phenotype of interest, we observed a pattern similar to that found 
for the phenotype of “any complication” (Table 3A, Figure 4). Although the strength of the 
linkage peaks in and outside the HLA region were attenuated compared with analyses using “any 
complication” as the phenotype, the telomeric peak (HLOD=2.43) and the HLA peak 
(HLOD=2.24) indicate strong linkage evidence. The drop in the HLOD score is due to the 
smaller sample size, but the location is identical to the location in the analysis with all 
complications. The peak centromeric to HLA did not demonstrate statistically significant 
evidence for linkage to the “retinopathy alone” phenotype (HLOD<1). The telomeric linkage 
peak for retinopathy alone was not observed when we performed linkage for “T1D” as the 
phenotype (Figure 2).  
 
4.4.5 Linkage analysis with nephropathy alone & neuropathy alone as the phenotypes 
For nephropathy alone, the evidence for linkage approached the “suggestive” threshold and is 
provided as supplemental data (Supplemental Appendix). For neuropathy alone, we observed no 
significant or suggestive evidence for linkage (data not shown).  
 
4.4.6 Stratification by HLA-DRB1 alleles among probands 
i. Linkage analysis with the presence of any complication as the phenotype 
In analyses using families stratified by the presence of DRB1*03:01 in the proband, we found 




suggest a protective effect for DRB1*03:01 on risk of complications (66 out of 156 families) 
(Table 3B, Figure 5A). The signal at HLA for “any complication” phenotype decreased from an 
HLOD score of 3.61 (unstratified) to 2.33 (when including only families with DRB1*03:01-
positive families), with an additional reduction in the HLA-telomeric linkage peak outside the 
HLA region (HLOD=3.27 for unstratified, HLOD=1.76 for DRB1*03:01-stratified). In contrast, 
the HLA-centromeric peak increased and reached the threshold for suggestive linkage 
(HLOD=1.53 unstratified, HLOD=1.96 DRB1*03:01-stratified) with the inclusion of only 
DRB1*03:01 positive families. The decrease in HLOD score might be attributed entirely to a 
decrease in sample size when dividing the dataset. Arguing against that explanation is a) the 
increase in the HLA centromeric peak in the reduced size sample (indicating a decrease in 
heterogeneity) and b) the notable HLOD score for the DRB1*04:01 families (see below). 
 
In a parallel analysis, including only DRB1*04:01 families, we observed a different trend than 
with the analysis using only families whose probands carries a DRB1*03:01 allele. Using 
comparable numbers of families to those used in the DRB1*03:01 stratified analysis (described 
above) (63 out of 156 families in DRB1*04:01-stratified analysis; 66 out of 156 families in 
DRB1*03:01-stratified analysis), we repeated the linkage analysis using families in which the 
proband was DRB1*04:01 positive  (which include heterozygous DRB1*03:01/DRB1*04:01) 
(Table 3B, Figure 5B). The linkage peak in the HLA region remained highly significant when 
only DRB*04:01 positive proband families were included in the analysis  (HLOD=4.15), even 
given the reduction in the total number of families. There were also two additional peaks outside 
of the HLA region at position 32.38 cM (HLOD=2.43) at position 42.6 cM (HLOD=3.68). The 




actually increased in comparison with the unstratified analysis, which was comprised of a larger 
sample of families. The HLA-centromeric peak decreased (from HLOD=1.53 unstratified to 
HLOD=1.43 DRB1*04:01-stratified) in comparison with the peak identified in the DRB1*03:01-
stratified analysis (HLOD=1.96). 
 
We then repeated the DRB1*04:01- and DRB1*03:01-stratified analyses but excluding families 
of probands with the DRB1*03:01/ DRB1*04:01 genotype (Table 3B, Figure 5C).  
 
With a pool of pure DRB1*03:01 positive families, (that is, with only DRB1*03:01/X proband 
families included (X=any allele but *04:01)), the linkage signals for both the HLA region as well 
as the peak outside the HLA region did not exceed 1.  
 
In contrast, when we exclude the heterozygous DRB1*03:01/DRB1*04:01 -carrying individuals 
from the analysis of DRB1*04:01 positive families, the HLOD for the HLA locus remained 
surprisingly high (HLOD=2.34), even with the severe reduction in total number of families, but 
with numbers still comparable to the DRB1*03:01 families. The peak telomeric to HLA remains 
high with an HLOD=2.47 (Table 3B, Figure 5D). Even with smaller sample sizes in this subset 
of families (without DRB1*03:01/DRB1*04:01 heterozygotes), the evidence for linkage remains 
high and implies an interaction between the HLA DRB1*04:01 allele and this broad region 
telomeric to HLA. With comparable numbers of families as those in the pure DRB1*03:01 
positive families (without DRB1*03:01/DRB1*04:01 heterozygotes), we retain HLODs 




regions that may be involved in expression of complications. These regions are not observed 
among DRB1*03:01-positive families.  
 
Of note, there are approximately equal proportions of complications among the DRB1*03:01-
positive families (75%) compared with the DRB1*04:01-positive families (74%) as well as the 
distribution of family structures being approximately equal between the groups. Among the 
DRB1*03:01-positive families, there are 31 families with 1 affected (T1D+complications) 
sibling and 31 families with 2 affected (T1D+complications) siblings. There are 2 families with 3 
affected siblings, 1 family has 4 affected siblings and 1 family has 5 affected siblings (66 total 
families). Among the DRB1*04:01-positive families, there are 32 families with 1 affected sibling, 
29 families with 2 affected siblings and 2 families with 3 affected siblings (63 total families). 
While retinopathy constitutes the majority of complications among affected individuals, there are 
also approximately equal numbers of nephropathy patients among the DRB1*03:01-positive 
families (n=43) compared with the DRB1*04:01-positive families (n=41). 
 
ii. Linkage analysis with retinopathy as the phenotype 
To determine if the presence of the DRB1*03:01 and DRB1*04:01 had the same effect on 
linkage evidence when the phenotype was “retinopathy alone” as with the “any complication” 
phenotype, we stratified families with retinopathy on the DRB1*03:01 and DRB1*04:01 status 
of the probands. 
 
For DRB1*03:01 positive families with retinopathy alone, we see a pattern of linkage peaks 




6A). The major peak is over the HLA region (HLOD=1.84); the peak centromeric to HLA 
remains distinct (HLOD=1.77). When we removed the DRB1*03:01/DRB1*04:01 heterozygotes 
so that there are no DRB1*04:01 alleles among probands, we observe an almost identical pattern 
to the linkage scan for “any complication” (Table 4B, Figure 6C), i.e, the 3 distinct peaks did not 
exceed HLODs of 1.  
 
The retinopathy phenotype follows the same pattern of linkage as we observed using the 
phenotype “any complication”, for both the DRB1*03:01 and DRB1*04:01-stratified analyses, 
but with diminished linkage signals. There is a small reduction in the sample size using 
retinopathy alone compared with “any complication”. It is possible that the reduced sample size 
is responsible for the decreased strength of the linkage signal for retinopathy alone.  
 
When we look only at the “retinopathy” phenotype, including only the DRB1*04:01 positive 
families, we see a pattern similar to what we observed for the “any complication” phenotype 
(Table 3B, Figure 6B). The linkage peak at the HLA locus remains significant (HLOD=3.18), 
but one HLOD unit lower than what we saw for “any complication” (HLOD=4.15). The second 
peak, telomeric to the HLA region, remains a significant signal for retinopathy (HLOD=2.97). 
The peak most distal (position 32.38 cM) to HLA is close to the threshold for suggestive linkage 
(HLOD=1.87). The peak centromeric to the HLA peak is dramatically diminished (HLOD<1). 
When we remove the DRB1*03:01/DRB1*04:01 heterozygotes, the telomeric peak closest to the 
HLA locus becomes the most distinct peak and very broad (peak linkage ranging from 
approximately 35-42 cM), exceeding an HLOD of 2 (Table 3B, Figure 6D). This region, 




of interest that lies outside of the HLA region involved in the expression of retinopathy. Further, 
as we showed in chapter 3, DRB1*03:01-carrying patients may be “protected” from the 
development of retinopathy. The fact that the linkage signal declines for retinopathy both in and 
near the HLA region, for families with a DRB1*03:01 positive probands, supports the finding of 
the protective effect and further strengthens the evidence that the loci at those two linkage peaks 
interact in some way with the susceptibility related to DRB1*04:01. 
 
iii. Linkage analysis with nephropathy alone & neuropathy alone as the phenotypes 
For nephropathy alone, stratified analyses approach the suggestive threshold for linkage and data 
are provided in the supplemental appendix. 
 
For neuropathy alone, we observed no evidence for linkage in either the unstratified or in the 
DRB1*03:01 and DRB1*04:01 stratified analyses (data not shown). However, the sample size of 
these families may be too small to expect a good signal. 
 
4.5 DISCUSSION 
This HBDI dataset constitutes one of the larger collections of multiplex T1D families in the 
country and perhaps the largest collection of family data on T1D complications in the world. 
Despite numerous reports of loci linked to T1D (8,23,25-34), few studies have performed linkage 
analysis using microvascular complications of T1D as the phenotype of interest (9,10,12,35). 
The majority of studies examining T1D or complications have done so using association analysis 
or affected-only sib-pair analyses (23,25,36-39). In this study, we used LOD score linkage 




phenotype of interest. Such linkage analysis has been shown to have the most power to detect 
loci important for disease expression and the greatest ability to give us information about the 
genetic characteristics of the phenotype and the existence of heterogeneity.  
 
The aim of this linkage analysis was to search for genomic regions that were linked to 
microvascular complications in general, and to each complication separately. Our initial analysis 
confirmed the linkage signal for the phenotype of T1D in this dataset, although we know of no 
other analysis that excluded the presence of complications in the families. The purpose for 
analyzing T1D alone as a phenotype was to determine whether genomic regions that were 
identified when complications were the phenotype could also be seen with the T1D phenotype. 
We confirmed the presence of the HLA locus in T1D (figure 2). Subsequently, we conducted a 
series of analyses to identify genomic regions that were linked to complications, regions that 
may be the same or different than the locus observed for the presence of T1D. This contrast 
ensured that any observed linkage peaks in which complications are used as the phenotype are, in 
fact, related to the expression of complications, rather than to the expression of T1D. In the 
subsequent analyses, using “any complication” as the phenotype, we identified three linkage 
peaks (Figure 3). The major peak was located at the HLA locus (seen with the T1D phenotype) 
and another, not previously reported peak, was telomeric to HLA. A third linkage peak was 
located centromeric to the HLA region. Though not quite suggestive of linkage (1<HLOD<2), it 
remained a distinct peak. We repeated this linkage analysis using T1D with retinopathy as the 
phenotype. We identified the same two major linkage peaks, but we found that the telomeric 




complication” phenotype analysis. The centromeric peak that we previously observed using “any 
complication” as the phenotype, disappeared when we used retinopathy as the phenotype. 
 
We did not find suggestive or significant evidence for linkage when using nephropathy or 
neuropathy as the phenotype. However, the sample size of families with these phenotypes may 
have been too small to expect a good signal. Retinopathy constituted the majority of 
complications in our families, so we had the greatest ability to locate linkage signals linked to 
retinopathy. It was most notable that in addition to the peak centered on the HLA locus, we 
identified two separate genetic influences for complications, lying outside the HLA region, one 
telomeric and one centromeric to the HLA region. Notably, these linkage signals were not 
observed when we used T1D alone as the phenotype. 
 
In a previous paper (Aim 2 - Lipner et al, in press, Human Immunology), we had identified 
DRB1*03:01 as a significant protective factor for complications, while DRB1*04:01, in certain 
subgroup analyses, demonstrated elevated risk for complications. In order to determine whether 
the DRB1*03:01 or DRB1*04:01 allele had differential effects on the expression of 
complications, we performed linkage on chromosome 6 using subsets of families, stratified 
according to the proband’s DRB1*03:01 or DRB1*04:01 status.  
 
When stratifying according to the proband’s DRB1 status, we acknowledge that all family 
members may not harbor the same allele as the probands. Using this stratification scheme 
however increases the likelihood that the allele will be found more frequently in those family 




approach has been used in previous linkage analyses to detect genetic heterogeneity, in which 
T1D families were divided based upon genetic marker criterion (40). A variation of this 
stratification approach has also been used in a linkage analysis to identify genetic interactions in 
T1D susceptibility (23,41).  
 
Using families whose probands were positive for DRB1*03:01, (for both phenotypes - any 
complication and retinopathy alone), we identified three linkage peaks. The HLA peak was the 
most dominant, followed by two previously unreported loci. We observed a peak telomeric to 
HLA, which approached the suggestive threshold for linkage, as well as a peak centromeric to 
HLA, which was suggestive of linkage. In the unstratified analyses using the “any complication” 
phenotype, the centromeric peak did not reach the threshold suggestive for linkage. However 
using only DRB1*03:01 positive families, the strength of the centromeric peak increased and 
was suggestive for linkage. Interestingly, when the phenotype is retinopathy, the centromeric 
peak disappeared in the unstratified analysis, but when we used only the DRB1*03:01 positive 
families, the centromeric peak not only appeared, but approached the threshold suggestive for 
linkage. 
 
To further explore the effect of DRB1*03:01 on complications’ expression, we obtained a pure 
pool of DRB1*03:01 positive families by restricting the analyses to families, in which the 
probands did not have DRB1*04:01, excluding DRB1*03:01/ DRB1*04:01 heterozygotes, (that 
is, with only DRB1*03:01/X proband families included (X=any allele but *04:01)). For both 
phenotypes, the linkage signal for all three peaks either did not reach or did not far exceed 




DRB1*03:01 is a protective factor for the development of complications (for the presence of at 
least one complication and for retinopathy alone). While it is possible that these decreased 
linkage peaks are simply the result of decreased power (i.e., fewer individuals among 
DRB1*03:01-positive families have complications), we cannot rule out the possibility that a 
higher prevalence of the DRB1*03:01 allele within families confers a decreased risk for 
developing complications, as we have seen in our previous analysis. 
 
To explore the influence of the HLA DRB1*04:01 allele, we performed the same linkage 
analyses using families whose probands were positive for DRB1*04:01. When we stratified on 
DRB1*04:01-positive families (for both phenotypes), the peak centromeric to HLA disappeared. 
Instead, we identified two peaks telomeric to HLA. The peaks that we observed based on the 
DRB1*03:01-positive families were only suggestive or below the threshold for linkage. However 
the peaks based on DRB1*04:01-positive families either reached or exceeded the significant 
threshold for linkage. The DRB1*04:01 families retain two distinct linkage peaks outside 
(telomeric) of HLA. For both phenotypes, the HLA peak, as well as the more prominent 
telomeric peak, both exceed the significant threshold for linkage. The more distal telomeric peak 
approaches (for retinopathy) or exceeds (“any complication”) the suggestive threshold for 
linkage. Despite a smaller sample size for the DRB1*04:01-stratified analysis compared with the 
unstratified analysis, not only do we still report significant evidence for linkage at the HLA locus 
and at the region telomeric to HLA, for both phenotypes, but the evidence for linkage in the 
DRB1*04:01-stratified analysis exceeds the evidence for linkage in the unstratified analysis with 
a larger sample size. When we remove the DRB1*03:01/DRB1*04:01 heterozygotes, thus 




though now the evidence is only suggestive of linkage. These data suggests that among 
DRB1*04:01-positive individuals, there may be a region of interest that lies outside of the HLA 
region involved in the expression of microvascular complications, especially for retinopathy.  
 
After stratifying families by the presence of DRB1*03:01 or DRB1*04:01 in the probands, we 
observed greatly diminished HLOD scores (when excluding DRB1*03:01/DRB1*04:01 
heterozygotes) compared with the unstratified linkage analyses for any complication and for 
retinopathy. One explanation for the change in HLOD scores could be attributed to a change in 
sample size. As sample size decreases, so do the HLOD scores, as we would to expect to observe 
among the DRB1*03:01 and DRB1*04:01-positive stratifications. While there was a substantial 
decrease in HLOD scores among the DRB1*03:01 positive families (including 
DRB1*03:01/DRB1*04:01 heterozygotes), we in fact see an increase in the HLOD scores when 
we use the DRB1*04:01 positive families (including DRB1*03:01/DRB1*04:01 heterozygotes). 
With comparable numbers of families, we observed dramatically different patterns of linkage 
peaks when using the DRB1*03:01-positive families compared with the DRB1*04:01-positive 
families, as well as dramatically different strengths of HLOD scores between these groups. Such 
differences would imply that the presence of these alleles represents a genetically distinct subset 
of influences on the expression of T1D related complications in general and specifically for 
retinopathy.  
 
We intended to test whether our reported LOD scores for DRB1*03:01-stratified families and 
DRB1*04:01-stratified families come from groups that are genetically distinct from each other at 




According to the PST, a statistically significant result would show that the genetic contribution 
of the marker locus being tested (in this case, the HLA locus) contributes unequally to the two 
groups, i.e., that there is genetic heterogeneity between the groups. Upon further examination of 
this test, we learned that the PST was designed specifically for two-point linkage analysis, and it 
would not be statistically valid to apply the PST to multipoint linkage analysis. Additionally, 
while we observe multiple peaks, this test is used to compare only one major peak in the region 
((42), S.E. Hodge, personal communication). To the best of our knowledge, there is currently no 
method to statistically test whether these groups are genetically different from one another. 
Ultimately, the LOD score differences between the DRB1*03:01-stratified and DRB1*04:01-
stratified groups can only be assessed in a qualitative manner, rather than a quantitative one. 
Using the “any complication” phenotype and only the DRB1*03:01-positive families, the LOD 
score at the HLA locus is 1.13 (HLOD=2.33). Using only the DRB1*04:01-positive families, the 
LOD score at the HLA locus for the same phenotype is 4.14 (HLOD=4.15), and 1.20 
(HLOD=3.61) for the unstratified linkage analysis. When the phenotype is retinopathy and we 
used the DRB1*03:01-stratified families, the LOD score at the HLA locus is 0.15 (HLOD=1.84). 
Using only the DRB1*04:01-stratified families, the LOD score at the HLA locus is 3.16 
(HLOD=3.18), and 1.66 (HLOD=2.24) for the unstratified linkage analysis. Even though we are 
unable to formally test for genetic heterogeneity between these groups, based on a qualitative 
assessment of these scores it appears that these differences are likely large enough to argue that 
the genetic contribution to the phenotype is not the same in the two groups. An alternative 
explanation may be that the phenotypic information content is different in the two groups, 




dissertation. Examining how differing phenotypic information influences the outcome of LOD 
scores could be another venue for research. 
 
4.5.1 Other linkage analyses 
A number of T1D linkage scans have been reported (23,25-28), but there have been only a few 
scans for complications and it is useful to contrast the results for T1D with the results for 
complications associated with T1D. All T1D linkage studies have reported evidence of linkage 
of T1D to the HLA region on chromosome 6p21. Concannon and colleagues reported a LOD 
score of 213 using approximately 2,500 multiplex families (26). Morahan and colleagues 
reported a LOD score of 398 using over 4400 affected sib-pairs (23). These exceedingly strong 
LOD scores reinforce the importance of the HLA complex in the etiology of T1D. Only a few 
linkage analyses aimed at identifying susceptibility to complications, specifically nephropathy, 
have been conducted (9,10,12,35). Igo and colleagues conducted a genome-wide linkage analysis 
for diabetic nephropathy using Caucasian multiplex families (10). Authors observed evidence 
suggestive of linkage (LOD=2.84) on chromosome 6p24.3 (24.9 cM), telomeric to the HLA 
region, which was not significant at the genome-wide level. This study however claimed a mixed 
study population of type 1 and type 2 diabetics. Iyengar and colleagues performed genome-wide 
linkage analysis for nephropathy using an affected sib-pair analysis in a mixed study population 
of type 1 and type 2 diabetics, but did not report evidence of linkage on chromosome 6 (35), 
consistent with the findings of this study. A third genome-wide linkage analysis using a 
discordant sib-pair analysis for nephropathy showed evidence for linkage, but not on 
chromosome 6 (9). Moczulski and colleagues performed a linkage study using 66 pairs of 




chromosomal regions previously implicated in nephropathy (12). These authors reported a 
susceptibility locus for diabetic nephropathy on chromosome 3q (LOD=3.1), but not on 
chromosome 6. Interestingly, all four nephropathy studies did not report linkage to the HLA 
region. There is conflicting evidence from case-control studies regarding the contribution of 
HLA, in particular, the DRB1*04:01 allele, to the risk of retinopathy and nephropathy. In a 
recent study examining the genetics of kidney disease (GoKinD), authors reported that 
DRB1*04:01 is a protective allele for nephropathy (43). While this was not a linkage analysis, 
but rather a case-control study, this finding intersects our results which indicate that 
DRB1*04:01 contributes to the expression of complications, in our case, to retinopathy 
specifically.  
 
I found no reports of linkage using T1D-related retinopathy as the phenotype of interest. While 
we found evidence for linkage on chromosome 6 in and outside of the HLA region for 
retinopathy, we have no literature for comparison. This analysis is the first study to present 
strong evidence of a genetic effect for retinopathy. The peak centromeric to HLA may in fact be 
influential among T1D patients carrying the DRB1*03:01 allele, but with our sample size, this 
remains an intriguing research question.   
 
Based on our findings as well as on the published literature, HLA may be involved in the 







4.6 CONCLUSION    
This is one of the largest linkage analyses for microvascular complications using multiplex T1D 
families conducted to date. Our aim was to identify loci that contribute to the expression of 
complications using families with T1D patients. We are confident that our signals are the result 
of complications rather than the known, strong linkage signal for T1D itself. Linkage analysis for 
T1D without complications as the phenotype did not reveal peaks outside the HLA region. In 
contrast, analyses using complications as the affected phenotype did show evidence for non-
HLA loci. However, the stratification results suggest that HLA itself does influence the 
expression of retinopathy.  
 
We showed that both HLA and non-HLA loci are involved in the expression of complications, 
specifically for retinopathy. We observed a dramatic alteration in linkage trends by stratifying 
according to the proband’s DRB1 status. Since the HLA locus is the major genetic contributor to 
the expression of T1D, it is not surprising to find that it is also involved in the expression of 
T1D-related complications. What is surprising, however, is the differential effect that stratifying 
on the presence of HLA DRB1*03:01 and DRB1*04:01 alleles has on complications expression, 
as reflected in the HLOD scores. We observed entirely different linkage trends seen for the 
DRB1*03:01 allele compared with the DRB1*04:01 allele. While we were unable to apply the 
predivided sample test to detect genetic heterogeneity in our dataset, the dramatic difference in 
LOD scores between the families who have probands with the DRB1*03:01 versus the 
DRB1*04:01 allele suggest that these sets of families comprise different genetic groups. We can 
speculate that while the HLA region is a major contributor to the expression of T1D, there may 




influences the expression of complications. The next step for this study would be to perform 
genome wide linkage analysis, stratified according to the proband’s DRB1 status. This approach 
may identify interaction between HLA alleles and other genomic regions on different 
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Figure 1. Distribution of DRB1*03:01 and DRB1*04:01 among families whose probands 

























Table 1. Number of families with affected (T1D + complications)-unaffected (T1D only) 
members. 
Affected-unaffected family members Nfamilies (%) 
1 affected-1 unaffected 68 (16) 
2 affected-0 unaffected  50 (12) 
0 affected-2 unaffected 210 (51) 
Other 87 (21) 







Table 2. Prevalence of clinical characteristics among 415 T1D families. 
Clinical characteristic Number (%) of individuals 
Total 2,008 (100.0) 
T1D + microvascular complications 239 (11.9) 
T1D + retinopathy 219 (91.6) 
T1D + nephropathy 87 (36.4) 
T1D + neuropathy 76 (31.8) 
T1D only 629 (31.3) 


















HLOD at  
centromeric 
peak 
Presence of any 
complication 
Nfamilies=156 




41.60 cM 2.43 52.37 cM 2.24 61.01 cM 0.54 
 
Table 3. B. DRB1*03:01 and DRB1*04:01 stratifications for each phenotype and the 
associated HLOD scores. 





HLOD at centromeric 
peak 
Presence of any complication    
DRB1*03:01-positive families 
Nfamilies=66 
1.76 2.33 1.96 
Pure DRB1*03:01-positive families 
Nfamilies=40 
0.48 0.56 0.80 
DRB1*04:01-positive families 
Nfamilies=63 
3.68 4.14 1.43 
Pure DRB1*04:01-positive families 
Nfamilies=38 
2.47 2.34 0.52 
Retinopathy alone    
DRB1*03:01-positive families 
Nfamilies=61 
1.41 1.84 1.77 
Pure DRB1*03:01-positive families 
Nfamilies=37 
0.51 0.45 0.59 
DRB1*04:01-positive families 
Nfamilies=59 
2.97 3.18 0.56 
Pure DRB1*04:01-positive families 
Nfamilies=35 








Figure 2. Phenotype: T1D 
 





Figure 3. Phenotype: Presence of any complication 
 
   
 






Figure 4. Phenotype: Retinopathy 
      








 Figure 5. DRB1*03:01/DRB1*04:01 stratifications. 
Phenotype: Presence of any complication. 
 





C. Families with DRB1*03:01-positive probands D. Families with DRB1*04:01-positive probands 
(No DRB1*04:01 positive individuals)   (No DRB1*03:01 positive individuals) 
 
 





Figure 6. DRB1*03:01/DRB1*04:01 stratifications. 
Phenotype: Retinopathy alone 
 




C. Families with DRB1*03:01-positive probands D. Families with DRB1*04:01-positive probands 
(No DRB1*04:01 positive individuals)   (No DRB1*03:01 positive individuals) 
 
 





Chapter 5: Summary and Conclusions 
 
Retinopathy, nephropathy, neuropathy are chronic microvascular complications that represent a 
major health burden associated with type 1 diabetes. Among individuals with type 1 diabetes, 50-
90% will develop retinopathy (1), 40% are at risk for developing nephropathy and, of those, 20% 
will progress to end stage renal failure (1,2). Another 30-50% of patients will develop some form 
of neuropathy (1). Further, the presence of one complication is highly associated with an 
increased risk of developing a second complication. Thus, determining the causes of these 
complications is an important public health priority. 
 
The role of genetic risk factors in the development of microvascular complications is not clearly 
understood. Although the role of HLA in type 1 diabetes susceptibility has been extensively 
illuminated, the possible influence of HLA alleles in T1D complications presents a murky 
picture. Some studies have reported significant associations of HLA class I or II alleles with 
retinopathy or nephropathy, while other studies have failed to report such associations. 
 
The overall aim of the thesis was to identify genetic factors associated with risk for 
microvascular complications in individuals with type 1 diabetes.  We hypothesized that known 
susceptibility alleles for T1D may also influence the expression and risk for T1D-related 
microvascular complications. By using the tools of both logistic regression and linkage analysis, 
we have shown strong evidence of genetic influences in complications on chromosome 6, and 





To accomplish this aim I first began by reviewing the literature on type 1 diabetes and 
microvascular complications (retinopathy, nephropathy, and neuropathy) (Chapter 2). I identified 
gaps and deficiencies in previous studies and provided the rationale for my analytic aims and 
methods. I then investigated genetic risk factors, specifically the HLA DRB1*03:01 and 
DRB1*04:01 alleles, associated with type 1 diabetes that may also influence the risk for 
complications. Cases were defined as T1D patients with the presence of at least one complication, 
while controls consisted of T1D patients who have been free of complications for at least 15 
years. I examined the association between known T1D HLA susceptibility alleles and risk for 
any complication, as well as the risks for retinopathy alone, nephropathy alone, and neuropathy 
alone and found significant differences in risk for different HLA alleles (Chapter 3). Finally, I 
performed linkage analysis to identify chromosomal regions that may contribute to the 
expression of complications. I performed genome-wide linkage analysis and tested 5,966 
markers for co-segregation with microvascular complications. The only chromosome that 
yielded statistically significant indications of loci related to complications was on chromosome 6. 
I used linkage analysis as a way to examine the evidence for several phenotypic classifications: 
1) the phenotype of T1D itself, 2) the presence of any microvascular complication, 3) retinopathy 
alone, 4) nephropathy alone, and 5) neuropathy alone (Chapter 4). A particular advantage in the 
dataset we used was that the long follow-up period assured that individuals who were diagnosed 
with type 1 diabetes without complications were, in fact, free of complications and were unlikely 







5.1. Summary of Findings  
In Chapter 2, I reviewed and evaluated the existing literature on the epidemiology, pathogenesis, 
clinical diagnoses, symptoms, risk factors, genetics, and familiality for type 1 diabetes and 
microvascular complications.  The highly varied geographic distribution of type 1 diabetes has 
been well documented and points to differences in allele and haplotype frequencies in different 
ethnic groups. Studies have found that some susceptibility alleles/haplotypes common in 
Caucasian populations are less common in Asian populations. However the effect of individual 
alleles/haplotypes is consistent across populations. This suggests that the variation in the 
worldwide prevalence of type 1 diabetes is primarily related to differences in the frequency of 
the risk alleles in different populations. As noted above, many studies have focused on genetic 
risk factors that contribute to the expression of T1D. However, the findings from studies of 
genetic risk factors for complications are inconsistent. Further, there have only been a few 
linkage scans performed attempting to identify chromosomal regions that co-segregate with 
complications. However, these studies examined either mixed populations of type 1 and type 2 
diabetics, or were limited to sib-pair analyses. 
 To summarize the background chapter: The influence of genetic risk factors (specifically the 
HLA region) on type 1 diabetes is well known, studies have been contradictory about the role 
those factors play in the development of microvascular complications. The objective of this 
dissertation was to fill these gaps in the type 1 diabetes literature 
 
In Chapter 3, I reported our findings from a series of logistic regression analyses examining 
known type 1 diabetes susceptibility alleles and their association with the presence of at least one 




the alleles with the highest risk for type 1 diabetes among Caucasians (DRB1*03:01 and 
DRB1*04:01) may also be susceptibility alleles for type 1 diabetes-related microvascular 
complications.  After controlling for important type 1 diabetes related covariates, including sex, 
age of T1D diagnosis and duration of T1D, we found that DRB1*03:01 was a significant 
protective factor for the presence of one or more complication, and more specifically, that this 
association was found only for retinopathy. The DRB1*04:01 allele appeared to have no effect 
on the risk of any complications. However, to isolate the effect of DRB1*04:01 by itself, we 
removed individuals carrying the DRB1*03:01, including those who were heterozygous for 
DRB1*03:01/ DRB1*04:01. When we included only the probands who were positive for at least 
one DRB1*04:01 allele, we observed a stronger association for DRB1*04:01 and the risk of 
retinopathy. This association with DRB1*04:01 and the risk of retinopathy may have emerged in 
the DRB1*04:01 carriers who did not have DRB1*03:01 because the protective effect of 
DRB1*03:01 masked the weaker positive effect of DRB1*04:01 on retinopathy expression. Our 
data also demonstrated a strong positive association between the HLA class I alleles, B*39:06 
and B*44:02, and complications. Only the B*39:06 allele showed a dramatic change in the 
estimate from the unadjusted model compared with the model adjusted for covariates. The results 
from this study indicate that the immune system may be involved in the mechanisms leading to, 
or protecting individuals with type 1 diabetes from the development of microvascular 
complications, and/or for retinopathy specifically. 
 
In Chapter 4, I used linkage analysis to identify loci on chromosome 6 that may contribute to the 
expression of microvascular complications. I found linkage markers that co-segregated 





First, we confirmed that alleles of the HLA region (50.8-52.3 cM) on chromosome 6 co-
segregated with T1D in our dataset. This was an important control that we used to compare with 
the results for linkage to complications. It also demonstrated that well-established markers for 
T1D were also a characteristic of our study sample. 
 
We then conducted linkage analysis using “the presence of any microvascular complication” as 
the phenotype. We identified a linkage peak on chromosome 6 at 42.85 cM that was at least 5 
cM telomeric from the HLA region and was distinct from it. In analyses examining each 
microvascular complication separately, we identified a distinct linkage peak outside (telomeric) 
of the HLA region for retinopathy alone that appeared to coincide with the peak for the “any 
complications” phenotype. While the linkage peak for retinopathy was slightly narrower than 
what we observed for the phenotype ‘any complication’, it was significant and, again, distinct 
from the HLA peak.  
For both phenotypes (any complications and retinopathy alone) we also observed a linkage peak 
centromeric to the HLA region when we stratified on families positive for the DRB1*03:01 
allele. However, this peak was not seen when we used only families positive for DRB1*04:01 in 
the analysis. There was a marked increase in the strength of the centromeric linkage peak when 
we used families positive for DRB1*03:01. However, we also observed further evidence that the 
DRB1*03:01 allele was protective. We found that, for both phenotypes, families with a 
DRB1*03:01-positive proband demonstrated diminished linkage signals in and outside 
(telomeric) of the HLA region, while families with a DRB1*04:01-positive proband maintained 




observation is compatible with our finding that DRB*03:01 is protective for complications, 
specifically for retinopathy.  It also suggests that there may be an interaction between the region 
centromeric to HLA and the HLA DRB1*03:01 allele that influences protection against the 
development of complications. 
 
In summary, we observed significant evidence for linkage at locations in and out of the HLA 
region for these phenotypes: T1D alone; the presence of at least one complication; and 
retinopathy alone.  Since the majority of our cases with complications were retinopathy cases, 
our evidence was strongest for retinopathy. The sample size for nephropathy and neuropathy 
may have been too small to detect a significant signal.  
 
To my knowledge, this is the first study to investigate both the association between T1D 
susceptibility alleles and microvascular complications and, in same study sample, perform 
linkage analyses to identify genomic regions that may contribute to the expression of 
complications. This study suggests that DRB1*03:01 and DRB1*04:01 may be involved in 
mechanisms leading to, or protecting T1D patients from, the development of microvascular 
complications. Further functional studies will be needed to elucidate the pathophysiological 
pathways that may be involved in the development of complications. 
 
5.2. Strengths and limitations 
These findings have multiple strengths as well as several weaknesses that must be considered in 





5.3. Strengths of the study 
This study used one of the largest databases of multiplex type 1 diabetes families in the country 
and is also the first study using one of the larger datasets in the world with multiplex T1D 
families that also has information on three microvascular complications (retinopathy, 
nephropathy and neuropathy). While most genetic studies obtain clinical and genetic information 
for only affected individuals, this study obtained clinical and genetic data from all family 
members, even those without type 1 diabetes. Thus we were able to use family members with 
T1D but without complications as a control group.  This type of study design vastly increases 
study power, as well increasing the analytic possibilities. 
Among other strengths of this study is the unique data set that allowed us to examine 
complications as the phenotype of interest. The vast majority of studies have used T1D as the 
phenotype of interest, rather than complications. 
 
5.4. Weaknesses of the study 
The lack of data on age of onset of complications was possibly the greatest limitation to the 
analyses. Using the presence/absence of complications provided a cruder measure for 
complications compared with using age of onset of complications. However our large sample 
size increased the power of the study and provided a solid indication that genes influence the 
expression of complications.  
These analyses are also limited by the self-reported diagnosis of both T1D and microvascular 
complications, although subjects were contacted periodically for health updates. The possibility 
exists that some T2D patients may have been misclassified as T1D. To characterize the extent of 




subjects (n=76), since the presence of autoantibodies in people with diabetes confirms an 
autoimmune response. Only five percent of patients classified as having T1D in this subsample 
tested negative for autoantibodies. Five percent misclassification of diabetes diagnoses is not 
unusual, and many studies have reported autoantibody negativity among T1D patients ranging 
from 3.5% to 10% (3,4).  
Lastly, because all patients in this study were Caucasian, findings from this study are 
generalizable only to Caucasian populations and are not generalizable to patients of other 
ethnicities, such as African-Americans, Asians or Latinos who may have different risk alleles for 
microvascular complications.  
 
5.5. Future research directions 
This dissertation provides a solid first step to illuminate specific genetic factors and genomic 
regions that may be involved in the expression of microvascular complications. Additional 
DRB1*03:01 and DRB1*04:01 stratified genome-wide linkage analyses should be performed to 
identify other genomic regions that may interact with HLA to influence the expression of 
microvascular complications. Further research also needs to be conducted in separate study 
populations to validate our findings. Confirmation of these results could provide greater insights 
into the mechanisms leading to the development of microvascular complications and point to 
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Figure 2. DRB1*03:01/DRB1*04:01 stratifications. 
Phenotype: Nephropathy alone 
 
A. Families with DRB1*03:01-positive probands  
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C. Families with DRB1*03:01-positive probands  
(No DRB1*04:01 positive individuals)    
 
D. Families with DRB1*04:01-positive probands 





Appendix 2. Genome-wide linkage analyses  
Phenotype: Retinopathy 
 
Figure 1. Chromosome 1 
 
 












































































































Figure 22. Chromosome 22 
 
 
